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INTRODUCTION 
 
Optic neuritis is a term used to refer to inflammation of the optic nerve. 
When it is associated with a swollen optic disc, it is called papillitis or anterior 
optic neuritis
1
. When the optic disc appears normal, the term retrobulbar optic 
neuritis or retrobulbar neuritis are used. In the absence of signs of multiple 
sclerosis or other systemic disease, the term optic neuritis refers to isolated, 
monosymptomatic, or idiopathic. It is likely that most cases of isolated acute optic 
neuritis are a forme fruste of multiple sclerosis.  Patients in whom optic neuritis 
occurs as an isolated phenomenon have a higher risk of developing multiple 
sclerosis at a later date than the normal population. Optic neuritis is also a part of 
the demyelinating syndrome called neuromyelitis optica or “Devic’s disease”. 
 
Incidence of optic neuritis in several studies ranges from one to six new 
cases per year per one lakh population. Patients with optic neuritis are typically 
young with a peak incidence in the third and fourth decade. Women are more 
commonly affected than men. Optic neuritis is characterised by sudden partial or 
complete loss of vision, loss of colour vision, pain on movement of the affected 
eye, afferent pupillary defect, normal or swollen optic nerve head and central 
visual field defects. 
 
Optic neuritis can spontaneously recover or can lead to permanent optic 
nerve damage leading to permanent visual loss. Spontaneous recovery can be 
speeded up by parenteral steroids (Optic Neuritis Treatment Trial) at appropriate 
time.  Permanent optic nerve damage can be prevented by this.  
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REVIEW OF LITERATURE 
 
Kirkham and Coupland – 1981 found that the most common findings after an 
attack of acute optic neuritis were optic atrophy, defective colour vision and 
prolonged pupil cycle time. 
Griffith (1897) and Gunn (1904) considered the central field to be always affected 
in patients with optic neuritis. 
Hierons and Lyle (1959) and Kennedy and Carroll (1960) found that optic neuritis 
occurring in children is more common in first and second decade of life.  
Kahana et al (1976) found that multiple sclerosis developed in only 13% of 
patients with anterior optic neuritis, compared with 60% of patients with 
retrobulbar optic neuritis. 
Bradley and Whitty (1967) believed that ultimate visual acuity after optic neuritis 
has no bearing on the subsequent development of multiple sclerosis. 
Kurland et al (1966) Bradley and Whitty (1967) Morrissey et al (1995) concluded 
that most of the adult patients with bilateral simultaneous optic neuritis have the 
same risk of developing multiple sclerosis as patients with unilateral optic neuritis. 
1988 – Optic Neuritis Treatment Trial - a cohort study of patients with acute 
unilateral optic neuritis followed up for 15 years to assess the prognosis of optic 
neuritis, the use of steroids to treat it and the subsequent risk of developing 
multiple sclerosis was started. 
2006 – Final examination of patients enrolled in ONTT was done. 
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EMBRYOLOGY 
 
OPTIC NERVE 
Axons 
The optic nerve develops from the embryonic optic stalk, which appears at 
the fourth week and connects the optic vesicle to the forebrain. As the stalk 
lengthens, it becomes thinner and the lumen is progressively occupied by the 
axons growing from the ganglion cells of the retina (the seventh week, 15-mm 
stage). In the meantime, the embryonic cleft closes at the sixth week of gestation. 
At the eighth week, axons fully occupy the stalk and reach the brain and a 
rudimentary optic chiasma is established. The mechanism by which the embryonic 
retinal ganglion cell axons reach the optic disc remains unclear. Many factors, 
such as the paired box containing the Pax2 gene the axon guidance molecule 
netrin-1 and other cell surface or extracellular matrix component may be involved 
in axon path finding mechanisms. Expression errors of these molecules lead to 
optic nerve hypoplasia
2
. The axons of the optic nerve are surrounded by myelin 
sheaths. Myelinization begins centrally, progresses in a centrifugal direction 
toward the eye, and terminates at the level of the lamina cribrosa. The myelin 
sheath is produced by oligodendrocytes, and myelinization is usually complete 
shortly after birth. 
 
Optic Nerve Sheaths 
The sheaths of the optic nerve begin to appear at the end of the seventh 
week. Thin, elongated mesenchymal cells surround the optic nerve (10-mm stage) 
and become a single compact layer by the 17-mm stage. The pia mater can be 
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identified by the ninth to tenth week of gestation (45- to 50-mm stage), followed 
by the dura mater at the fifth month of gestation and the arachnoid sheath by the 
sixth and seventh months of gestation. Both the pia mater and the arachnoid are 
derived from the neural crest. (Figure 2) 
 
Glial Element 
At the ninth week (45-mm stage), the glial cells in the optic nerve are 
oriented in rows between the fascicles of axons. A peripheral layer of glial cells 
forms a glial limitans made up of immature astrocytes with glial filaments under 
the thin meningeal sheath. The glial limitans is separated from the pia mater by a 
complete basement membrane. Astrocytes line the connective tissue septa and 
capillaries. They are distributed among the axons at the 200 mm stage. 
 
It has been suggested that optic nerve oligodendrocytes may originate from 
the astrocytes that occupy the optic nerve before myelinization rather than 
exclusively from glioblasts
2
. The glial cells in the optic nerve and retina may 
differentiate into astrocytes and oligodendrocytes.  
 
It is not clear whether microglia originate from mesoderm or ectoderm, 
although most studies support a mesodermal origin. Under the electron 
microscope, microglia are identified in the optic nerve at the eighth week of 
gestation. Most microglia are found within bundles of axons, and there is no 
preferential distribution in relation to blood vessels or to the pial surface at any 
stage of development. The percentage of microglia present increases from 1.3% at 
8 weeks to 2.7% at 18 weeks.  
5 
 
Vasculature 
The development of capillaries in the optic nerve and the CNS is similar. 
At the 11th week (65mm to 73mm stage), vessels and connective tissue from the 
pia mater begin to enter the proximal optic nerve and slowly enlarge the 
connective tissue septa during the next few months. The capillaries within the 
optic nerve are separated from the axons by a relatively complete astrocyte sheet 
and perivascular space. In the 18th week (160mm stage), vascularization of the 
optic nerve is completed, and there may be anastomoses anteriorly by this stage 
with the arterial circle of Zinn-Haller. The capillaries within the neural tissue are 
surrounded by astrocytes and by a partially fused double basement membrane of 
both endothelial and glial cell origin. The basement membrane along the 
astrocytic foot processes defines the limits of the connective tissue septa along the 
neural tissue
2
.                      
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Figure 1: Visual pathway 
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Figure 2: Development of optic nerve 
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ANATOMY OF THE OPTIC NERVE 
 
The optic nerve is not really a nerve as are the peripheral nerves. It is a 
part of the central nervous system. As such it is a tract and its axons are 
myelinated by oligodendrocytes, not schwann cells. Optic nerve carries about 1.2 
million retinal ganglion cell axons. The axons form the nerve fibre layer and 
eventually synapse in the lateral geniculate body. The optic nerve is about 50 mm 
long. It is divided into four sections – intraocular, intraorbital, intracanalicular, 
and intracranial
3
. These zones have very different microanatomic arrangement 
with elements of neuroectoderm and mesoderm intermingled. (Figure 3-5) 
 
Intraocular Optic nerve (Optic nerve head):  
Axons of the retinal ganglion cells form bundles that constitute the nerve 
fibre layer which then converges like spokes of a wheel at the optic nerve head. It 
is about one mm long. Its diameter is 1.5 mm horizontally by 1.8 mm vertically at 
the level of the retina. The intraocular optic nervc can be further divided into three 
anatomically distinct zones – retinal or prelaminar (anterior), the choroidal or 
laminar portion (middle), and the scleral or retrolaminar portion (posterior). Optic 
nerve includes an oval grouping of 200 to 300 holes that perforate the choroid and 
sclera forming a specialized structure the lamina cribrosa through which all retinal 
axons pass to exit the eye. The anterior surface of the nerve head is the clinically 
visible optic disc. The appearance of the disc depends upon two important 
features: size of the scleral canal and the angle of exit of the canal from the eye.  
 Surface area is supplied by retinal capillaries. 
 Prelaminar portion is supplied by the peripapillary choroidal vessels. 
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 The laminar portion of the optic nerve head receives its blood supply from 
circle of Zinn, formed by short ciliary vessels.  
 The postlaminar area is supplied by branches of pial plexus from central 
retinal artery.  
 
Intraorbital optic nerve: 
The orbital portion of the optic nerve is 25 mm in length and thus exceeds 
the antero-posterior distance from the back of the globe to the optic foramen by 
about eight mm. The redundancy of the sinuous optic nerve permits it to move 
freely during eye movements. There is thus an allowance of upto nine millimeter 
proptosis before the optic nerve acts as a tether and distorts the globe. The optic 
nerve increases in diameter from three mm at its exit from the globe to about 4.5 
mm at the orbital apex. Throughout the orbital course the nerve is surrounded by 
dura, arachnoid and the pia mater. The subarachnoid space is continuous with the 
intracranial subarachnoid space and thus contains CSF.  It is supplied by recurrent 
branches of the short posterior ciliary arteries and capillary branches of the 
ophthalmic artery. Capillaries are also supplied anteriorly by branches from the 
central retinal artery, which pierce the optic nerve 10-15 mm from the nerve globe 
junction.  It is also supplied by the anastomotic branch from the external carotid 
artery – middle meningeal artery, superficial temporal and transverse facial artery.  
 
Intracanalicular optic nerve (intraosseous optic nerve): 
The length of the intracanalicualr part is 10 mm.  The optic nerve enters 
the optic canal through its anterior opening in the apex of the orbital roof about 5 
cm posterior and 1.5 cm inferior to the supraorbital margin. This anterior opening 
10 
 
is called the optic foramen. The optic canal transmits the optic nerve, ophthalmic 
artery, some filaments of the sympathetic carotid plexus and the orbital extension 
of the cranial leptomeninges. This tight space in the optic nerve is particularly 
vulnerable to trauma
4
. Ophthalmic artery crosses the optic nerve inferiorly from 
medial to lateral side in the dural sheath. This nerve is supplied only by periaxial 
system of vessels. The pial plexus is supplied mainly from the branches from the 
ophthalmic artery.  
 
Intra cranial optic nerve: 
The length of the intracranial optic nerve is variable (4-15 mm) depending 
on the position of the chiasma in relation to the sella turcica. Its average diameter 
is about 4.5 to 5 mm, but it is flattened and thus is wider in the horizontal plane 
than in the vertical plane.  Immediately above the nerve lie the anterior cerebral 
and anterior communicating arteries and above this lie the olfactory nerve and the 
frontal nerve. Just lateral to each nerve lies the internal carotid artery and 
ophthalmic artery arises from the internal carotid artery just below the optic 
nerve
5
. Just under each optic nerve and above the pituitary gland lies the planum 
sphenoidale. The course of the intracranial optic nerve is upward and at 45
0
 angle 
to reach the chiasma. This part of the optic nerve is supplied by the pial plexus of 
vessels from branches of internal carotid artery, anterior cerebral artery or from 
the anterior communicating artery. 
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Figure 3: Optic nereve in optic canal 
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Figure 4 : Blood supply of optic nerve 
 
Figure 5: Covering membranes of Optic nerve 
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PHYSIOLOGY OF OPTIC NERVE 
 
SYNAPTIC TRANSMISSION 
Retinal ganglion cells receive synaptic input from bipolar and amacrine 
cells.  The synapses from bipolar and amacrine cells primarily use glutamate as 
the major excitatory neurotransmitter. Within the retina the levels of glutamate are 
controlled by Müller cells, which have glutamate transporters and also contain the 
enzyme glutamine synthetase, which converts glutamate to the amino acid 
glutamine. 
 
EXCITOTOXICITY 
               Retinal ganglion cells are particularly susceptible to high levels of 
glutamate in the extracellular space. This causes cell death mediated via 
overexcitation, or excitotoxicity.  
 
AXONAL CONDUCTION 
Action Potentials 
The primary function of the optic nerve is to carry information from the 
retina to target areas within the brain. The retinal ganglion cells and their axons 
are the first neurons in the transmission of visual information from the eye to use 
action potentials as the mechanism for transmission. Conduction down the 
individual axons occurs via the same biophysical mechanisms that occur in any 
myelinated axon. 
              
14 
 
The mechanism of axonal conduction depends on action potential. In the 
process of transmission of an action potential there is movement of sodium and 
potassium ions along their concentration gradients
6
. If action potentials continued 
indefinitely, the sodium and potassium concentrations would reach equilibrium 
across the axonal membrane, resulting in loss of their concentration gradients and 
blocking conduction. Therefore, to re-establish their concentration gradients, there 
is a relatively slow redistribution process of these ions via the Na+ K+ ATPase 
takes place. This is a highly energy-dependent process and will not happen if 
axonal metabolism is pathologically disturbed. 
 
Role of Myelin 
               Myelin adds an additional complexity to axonal conduction. Myelin has 
two physiologic properties. It increases the resistance and decreases the 
capacitance of the axon. Ionic channels are not distributed uniformly along a 
myelinated axon. Instead, the channels are segregated into patches located within 
the small areas where the axon is unmyelinated. These are called nodes of 
Ranvier. 
                 
Conduction in a myelinated axon, therefore, becomes much faster, because 
the depolarization of the axon at one node leads to depolarization at the next node 
by the intrinsic conduction within the axon, instead of by sequential opening of 
channels along the axon. The depolarization, thus, “jumps” from one node to 
another; this is called saltatory conduction. 
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In cases of acquired loss of myelin, for example in idiopathic optic 
neuritis, a common inflammatory optic neuropathy, there is abnormal conduction 
because of the changes in resistive and capacitive properties of the membrane 
brought about by demyelination. Axonal conduction becomes slowed and in some 
cases may be blocked (“conduction block”), both of which result in decreased 
visual function. Another phenomenon peculiar to demyelination is worsening of 
vision with heat or exercise, called Uhthoff's phenomenon
7
. Increased 
temperature and exercise are thought to decrease the sodium channel open-time 
during depolarization, resulting in less charge entering the axon and a decreased 
likelihood that an adjacent section of demyelinated axon will be able to depolarize 
enough to cause opening of its own voltage-sensitive sodium channels. This leads 
to temperature-sensitive conduction block. 
 
Axonal transport occurs in two directions, orthograde  and retrograde. 
Axonal transport may be affected in disease, possibly potentiating nerve injury, 
such as in experimental allergic encephalomyelitis or glaucoma.   Important 
clinical correlations of altered axonal transport are in disc edema (in which 
blockage of axonal transport has been observed to occur, for example, with ocular 
hypotony or increased intracranial pressure) and in optic neuritis. 
16 
 
OPTIC NEURITIS 
 
The term optic neuritis refers to inflammatory optic neuropathy that 
accompanies demyelinating disease. When it is associated with swollen optic disc, 
it is called papillitis or anterior optic neuritis. When the optic disc appears normal, 
the terms retrobulbar optic neuritis or retrobulbar neuritis are used.  In the absence 
of signs of multiple sclerosis (MS) or other systemic disease the optic neuritis is 
referred to as isolated, monosymptomatic, or idiopathic. The pathogenesis of 
isolated optic neuritis is presumed to be demyelination of the optic nerve, similar 
to that seen in multiple sclerosis. It is likely that most cases of isolated acute optic 
neuritis are a “forme fruste” of MS7. 
 
Optic neuritis can be caused by disorders other than MS and related 
demyelinating diseases. In addition, two unusual variants of optic neuritis can 
occur in some patients. “Neuroretinitis” is a term used to describe inflammatory 
involvement of both the intraocular optic nerve and the peripapillary retina. They 
show optic disc swelling, extensive retinal edema, haemorrhages, and hard 
exudates (lipid) in the macula in a star-shaped pattern.  Optic perineuritis also 
called perioptic neuritis describes inflammatory involvement of the optic nerve 
sheaths without inflammation of the nerve itself associated with optic disc 
swelling that is unassociated with visual complaints.  
 
Optic neuritis can be described as
8
 
I) Idiopathic and primary demyelinating optic neuritis 
1. Acute idiopathic demyelinating optic neuritis 
17 
 
2. Chronic demyelinating optic neuritis 
3. Asymptomatic (subclinical) demyelinating optic neuritis 
4. Neuromyelitis optica (Devic’s disease) 
5. Optic neuritis in myelinoclastic diffuse sclerosis 
II) Secondary causes of optic neuritis 
1. Viral and bacterial infections 
2. After vaccination 
3. Sarcoidosis 
4. Syphilis 
5. HIV associated optic neuritis 
6. Systemic lupus erythematosus 
7. Lyme disease 
8. Sinus disease 
 
Idiopathic and primary demyelinating optic neuritis 
Acute idiopathic demyelinating optic neuritis 
Acute demyelinating optic neuritis is far by the most common type of optic 
neuritis that occurs throughout the world. It is the type that is best known and 
understood. Much information about optic neuritis was obtained from a 
multicenter study called “The Optic Neuritis Treatment Trial (ONTT)”.  
 
Symptoms of optic neuritis : 
The major symptoms in patients with acute optic neuritis are loss of central 
vision and pain in and around the affected eye.  
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1. Loss of central vision 
2. Loss of visual field 
3. Ocular or Orbital pain 
4. Positive visual phenomenon 
 
1. Loss of Central Vision: 
              Loss of central visual acuity is the major symptom in most cases 
of acute optic neuritis. Loss of vision is usually abrupt, occurring over 
several hours to several days. Progression for a longer period of time can 
occur but should make the clinician suspicious of an alternative disorder. 
The degree of visual loss varies widely. In some cases, visual acuity is 
minimally reduced, whereas in other cases, there will be complete 
blindness with no perception of light. The blurring of vision is 
predominantly central. The visual loss is monocular in most cases, but 
both eyes may be simultaneously affected particularly in children.  
2. Loss of Visual Fields: 
             Not all patients with acute optic neuritis have loss of central 
vision. Some patients have loss of peripheral vision usually in a particular 
area of the visual field, such as the inferior or superior region
9
. 
3.  Ocular or Orbital pain: 
             Pain in or around the eye is present in 90% of patients with acute 
optic neuritis. It is usually mild but it may be extremely severe than the 
loss of vision. It may precede or occur concurrently with visual loss. It is 
usually exacerbated by eye movement and generally lasts no more than  
few days. The pain is caused by inflammation or swelling in the optic 
19 
 
nerve sheaths that are innervated by small branches of the trigeminal 
nerve. It is hypothesized that the pain is initiated by inflammation or 
swelling in the optic nerve in the apex of the orbit, where the extraocular 
muscles are firmly attached to the sheaths of the nerve. The pain is more 
commonly present in retrobulbar neuritis than papillitis. The presence of 
pain is  helpful in differentiating optic neuritis from anterior ischemic optic 
neuropathy, particularly when it is severe and when it occurs or worsens 
during movement of the eyes.  
4. Positive Visual Phenomenon: 
            Patients with optic neuritis experience positive visual phenomena, 
called photopsia. This may be present both at the onset of their visual 
symptoms and during the course of the disease. They are spontaneous 
flashing black squares, flashes of light, or showers of sparks
10
. 
 
Uhtoff’s symptom   
Following episode of optic neuritis, some patients describe transient visual 
blurring during a hot bath, or during emotional stress. This is most common in 
patients with other evidence of multiple sclerosis, but is also experienced by 
patients recovered from optic neuritis, and in patients with Leber’s hereditary 
optic neuropathy. Some patients have improvement of visual symptoms with cold. 
Two major hypotheses regarding this phenomenon are  
1. Elevation of body temperature interferes directly with axon conduction. 
2. A Rise in body temperature releases a chemical substance that interferes 
with conduction
12
. 
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Physical effort produced a short lasting reduction in the amplitude of the 
VEP and in the visual acuity in patients with multiple sclerosis with a history of 
Uhthoff’s symptom. In patients with multiple sclerosis without a history of 
Uhthoff’s symptom neither visual acuity nor any aspect of VEP was changed. It 
has been proposed that demyelinated nerves may be susceptible not only to 
temperature changes but also to metabolic changes in the environment. 
 
Signs of Optic neuritis:  
Visual acuity  
The severity of visual acuity loss varies from a mild reduction to no light 
perception
13
.  
 
Colour Vision (Figure 6) 
              Colour vision is almost always abnormal in patients with optic neuritis 
and is usually more severely affected than visual acuity itself. The reduction in 
colour vision is much worse than would be expected from the level of acuity. So 
testing of colour vision may be particularly useful in diagnosing optic neuritis in 
patients with minor visual loss. Ishihara pseudo isochromatic colour plates could 
detect colour vision defects in eyes with retrobulbar optic neuritis and normal 
appearing optic discs. A more sensitive test for colour vision, the Farnsworth-
Munsell 100-Hue test, is best for detection of optic neuropathies, including optic 
neuritis. The pattern of colour defects found in patients with congenital colour 
blindness is much different from that of acquired colour defects from optic 
neuropathy. 
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Contrast Sensitivity and Brightness sensitivity (Figure 7) 
Contrast sensitivity is almost always abnormal in patients with optic 
neuritis. Patients with optic neuritis also have a reduced sensation in the affected 
eye
14
. This is tested by simply asking  the patients to compare the brightness of a 
light shined in one eye and then another or by performing more complex testing 
with a flickering light the frequency of which can be varied between 50 and 0 Hz.  
 
Visual Field 
Central field is almost always affected in optic neuritis. Central and 
paracentral scotomas, with and without peripheral extension, comprised of  90% 
of field defect. Almost any type of field defect can occur in optic neuritis 
including an arcuate defect, a caecocentral scotoma, a superior or inferior 
altitudinal defect and a left or right hemianopic defect. They may also have diffuse 
loss of sensitivity throughout the visual field.  
 
Pupillary Reaction 
A relative afferent pupillary defect is almost always present in patients 
with acute optic neuritis, whether anterior or retrobulbar. The only exception to 
this rule is the patients with a previous attack of optic neuritis in the fellow eye or 
who has subclinical (asymptomatic) optic neuritis in the fellow eye
15
. Here, 
damage to the optic nerve in the fellow eye may offset the damage from acute 
optic neuritis in the affected eye (even when there is asymmetry of visual function 
by clinical testing), and there will be no evidence of relative afferent pupillary 
defect. In cases of apparent optic neuritis with no relative afferent pupillary defect 
by swinging flash light, this defect can be uncovered by use of neutral density 
filters.  
22 
 
Figure 6: Contrast sensitivity – reduced in optic neuritis 
 
Figure 7: Red Desaturation  
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Slit lamp biomicroscopy and posterior segment inflammation: 
This is almost always normal in patients with demyelinating optic neuritis. 
There may be few cells in the vitreous overlying the optic disc, but there is rarely 
a  significant cellular reaction. In anterior optic neuritis (papillitis) due to causes 
other than demyelination such as sarcoidosis, tuberculosis, syphilis, or Lyme 
disease, a significant vitritis may be present.  
 
Ophthalmoscopic appearance: 
About 20 – 40% of patients with acute optic neuritis have some degree of 
disc swelling.  In the ONTT, optic disc swelling was observed in 35% of the 
patient. Sometimes the disc swelling is so severe that it mimics the choked disc 
seen in patients with papilledema. The degree of disc swelling does not correlate 
with the severity of either visual acuity or visual field loss
16
. Disc or peripapillary 
haemorrhages are uncommon in acute optic neuritis, as opposed to AION in 
which they more frequently accompany disc swelling.  In some patients with 
anterior optic neuritis, vitreous cells may be noted especially in the vitreous 
overlying the optic disc. When the cellular reaction is extensive etiologies other 
than multiple sclerosis should be considered. When macular or peripapillary hard 
exudates accompany the disc swelling other conditions such as neuroretinitis 
should be considered. Sheathing of retinal veins may occur in acute optic neuritis 
caused by certain conditions, including multiple sclerosis and sarcoidosis. Many 
of the patients with idiopathic or demyelinating acute optic neuritis have a normal 
optic disc in the affected eye, unless they had a previous attack of acute optic 
neuritis or have an ongoing chronic optic neuritis. With time, the optic disc 
becomes pale, even as the visual acuity and other parameters of vision improve. 
24 
 
The pallor may be diffuse or located to a particular portion of the disc, most often 
the temporal region.   
 
Other Tests of Optic Nerve Function: 
Other tests of optic nerve function including contrast sensitivity, visual 
evoked potential, and other psychophysical tests are almost always abnormal in 
patients with acute optic neuritis. Yet these tests rarely need to be performed for 
diagnosis of optic neuritis if other parameters are carefully evaluated. VEP is 
useful in distinguishing anterior optic neuritis from AION. The amplitude of the 
N95 peak was abnormally reduced for every eye affected with AION, whereas it 
remained normal in eyes with acute anterior optic neuritis
18
.  
 
Visual function in the other eye: 
Several studies have reported that asymptomatic visual dysfunction may 
be detected in the fellow eye of a patient with acute unilateral optic neuritis. The 
majority of fellow eye deficits resolved over several months, suggesting that such 
abnormalities may be caused by subclinical acute demyelination in the fellow 
optic nerve. 
 
Evaluation of patients with Acute Optic Neuritis 
After through general examination and ocular examination, colour vision, 
field charting, and contrast sensitivity examinations are carried out. By visual 
acuity, pupillary reaction, colour vision, contrast sensitivity and fundus clinical 
diagnosis of optic neuritis is made.  
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Complete hemogram is done to rule out infectious and inflammatory cause 
of optic neuritis. Investigations like Chest X-Ray, Mantoux test are done to rule 
out tuberculosis. VDRL is done to rule out syphilis.   
 
FFA are done in patients in whom diagnose is not clear to differentiate 
optic neuritis from AION, and other toxic neuropathies. 
 
In VEP when there is prechiasmal demyelination, a delay in the 
conduction occurs which can be measured from the occipital electrodes as an 
abnormal P100 latency
19
. The amplitude of the P100 peak is measured; a decline 
in amplitude corresponds with loss of axons. While decreased amplitude implies 
about disease pathogenesis, activity, and recovery, it is the VEP latency that is 
used as a clinical test. 
 
MRI is indicated in atypical cases, bilateral cases and recurrent cases.  
MRI brain shows thickened optic nerves indicating optic nerve inflammation. It 
shows demyelination especially in periventricular region suggestive of multiple 
sclerosis.  
 
Management Recommendations for patients with presumed acute 
optic neuritis: 
Treatment with intravenous methylprednisolone 250 mg 6
th
 hourly or 1 
gm/day in a single dose for three days, followed by a two week course of oral 
Prednisolone 1mg/kg/day with a rapid taper for patients with acute optic neuritis if 
brain MRI demonstrates multiple signal abnormalities in the periventricular white 
matter consistent with multiple sclerosis. However oral Prednisolone in standard 
dosage alone should be avoided to prevent recurrence
20
.  
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OPTIC NEURITIS TREATMENT TRIAL (ONTT) 
 
The optic neuritis treatment trial is a multicenter controlled clinical trial 
that was funded by the National Eye Institute of the National Institutes of Health 
in the United States. In this trial 455 patients with acute unilateral optic neuritis 
were enrolled. The primary objective of the trial was the assessment of the 
efficacy of corticosteroids in the treatment of optic neuritis. It also gives some 
information about the clinical profile of optic neuritis, its natural history and its 
relationship to MS
22
. 
 
Inclusion criteria in ONTT included a clinical syndrome consistent with 
unilateral optic neuritis (including a relative afferent pupillary defect and a visual 
field defect in the affected eye), visual symptoms of eight days or less, no 
previous episodes of optic neuritis in the affected eye, no previous corticosteroid 
treatment for optic neuritis or MS, and no evidence of a systemic disease other 
than MS as a cause for the optic neuritis
25
.  
 
Patients were assigned to one of three treatment groups: 
1. Oral prednisone (1 mg/kg/day) for 14 days 
2. Intravenous methyl prednisolone sodium succinate (250 mg QID for three 
days) followed by oral prednisone (1mg/kg/day) for 11 days  
3. Oral placebo for 14 days 
Methods of examination: 
Rate of visual recovery and visual outcome were assessed by 
1. Snellen acuity with a retroilluminated Bailey-Lovie chart at four meters 
27 
 
2. Colour vision with the Farnsworth-Munsell 100-hue test26 
3. Contrast sensitivity with the Pelli-Robson chart 
4. Perimetry with the Humphrey Field Analzer (program 30-2) and 
Goldmann perimeter.  
 
Complete neurological examination was performed at study entry, after six 
months, after one year, and then yearly. Clinically definite MS was diagnosed 
when a patient develops new neurological symptoms attributable to demyelination 
in one or more regions of the central nervous system, other than new optic neuritis 
in either eye, occurring atleast four weeks after the optic neuritis at study entry 
and lasting more than 24 hours with abnormalities documented on neurologic 
examination.  
 
Observation of ONTT: 
1. Most patients in all three treatment groups had a good recovery of vision. 
2. After six months of follow up, the median visual acuity in each age group 
was 20/60 and less than 10% of the patients in each group had a visual 
acuity of 20/50 or worse.  
3. One year after the onset of visual symptoms, there was no significant 
difference in mean visual cuity, color vision, contrast sensitivity, or visual 
field. 
4. Patients treated with the regimen intravenous methyl prednisolone 
followed by oral prednisolone recovered vision considerably faster than 
patients treated with oral placebo. 
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5. The benefit of this treatment regimen was greatest in the first 15 days of 
follow up and decreased subsequently. 
6. Patients treated with oral prednisone alone had an increased rate of 
recurrent attacks of optic neuritis in the previously affected eye and an 
increased rate of new attacks of optic neuritis in the fellow eye compared 
with patients in the other two groups.  
Oral Prednisolone in a dose of 1 mg/kg/day did not speed recovery of 
vision compared with no treatment, and  did not improve ultimate visual 
acuity, compared   with no treatment. It produced a higher rate of 
recurrence and new attacks of optic neuritis than no treatment
26
.  
7. Patients treated with intravenous followed by oral corticosteroids regimen 
had a reduced rate of development of clinically definite multiple sclerosis 
during the first two years. The clinical benefit of the intravenous treatment 
lessened over time such that at three years of follow up, there was no 
significant difference in the rate of development of MS among the 
treatment groups.  
8. Benefit of the treatment was only seen in patients who had significantly 
abnormal brain MRI at the time of onset of the optic neuritis.  
9. Ultimately the group concluded that there is no treatment for acute 
demyelinating optic neuritis that can improve the ultimate the visual 
prognosis compared with the natural history of the disorder
27
.  
10. Recurrent attacks of optic neuritis were reported within five years in 20% 
patients in ONTT. The likelihood of visual acuity returning to normal 
decreases with each recurrence.  
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Visual prognosis 
1. Among the patients enrolled in the ONTT who received the placebo, visual 
acuity began to improve within three weeks of onset in 79% and within 
five weeks in 93%.  
2. There is some correlation between the severity of visual loss and the 
degree of eventual recovery. Factors such as age, gender, optic disc 
appearance and pattern of the initial visual field defect do not appear to 
have any appreciable effect on the visual outcome.  
3. Even those patients with improvement in visual function to normal may 
complain of movements induced photopsias and may have persistent 
visual deficits when tested using more sensitive clinical, 
electrophysiologic or psychophysical test.  
4. The most common findings after an attack of acute optic neuritis were 
optic atrophy, defective colour vision and a prolonged pupil cycle time.  
5. Most patients recover to normal or near normal visual acuity.  
6. Persistent disturbances of colour vision are present in a high percentage of 
eyes with otherwise resolved optic neuritis. 
7. Residual visual field defects are usually present in eyes after resolution of 
acute optic neuritis even when visual acuity has returned 20/20 or better. 
After an attack of retrobulbar optic neuritis there is normal kinetic 
perimetry but abnormal static perimetry with good visual acuity recovery.   
8. Contrast sensitivity remains abnormal regardless of the degree of the 
degree of visual recovery in most eyes after resolution of acute optic 
neuritis. Contrast sensitivity is often abnormal in cases of multiple 
sclerosis in which there has not been overt acute optic neuritis. This 
30 
 
suggests that these eyes have subclinical optic nerve demyelination that 
was not necessarily detected by testing of other types of visual function.    
9. The subjective visual complaints of the patients correlated better with 
impaired contrast sensitivity than with any other measure of visual 
function, including visual acuity, colour vision, and visual field.  
10. Stereopsis is worse in optic neuritis compared to reduction in visual acuity 
in most of the cases. 
11. Many patients with unilateral acute optic neuritis have a persistent relative 
afferent pupillary defect on the affected side, even when excellent 
recovery of vision has occurred.  
12. Many cases of resolved optic neuritis had a persistent reduction in the 
amplitute of the VEP.  
13. Optic disc pallor is most often present when visual recovery has been 
incomplete and is often present even when recovery is excellent.  The 
pallor is usually temporal. 
14. More common than optic atrophy is the development of defects in the 
retinal nerve fiber layer after an attack of acute optic neuritis. Most 
patients develop such defects, which may be diffuse, localized to the 
papillomacular bundle, or isolated defects in the arcuate regions.  
15. Regarding subjective visual complaints, despite the often excellent 
measured recovery of visual function after an attack of acute optic neuritis, 
many patients still complain of difficulties with vision. This is mainly due 
to subtle abnormalities in the visual field that may be difficult to detect 
with standard static perimetry where patients experience abnormally rapid 
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disappearance of focal visual stimuli and abnormally rapid fatigue in 
sensitivity.  
 
Neurologic Prognosis: 
1. The risk of developing MS in patients who experience an attack of acute 
optic neuritis is only about 30% in patients followed 5-7 years after the 
attack of optic neuritis but eventually increases to about 75% in women 
and 34% in men with longer follow up.   
2. The risk of MS was higher in women than in men. 
3. The majority of patients, who develop MS after an attack of optic neuritis, 
do so within seven years of onset of visual symptoms. 
4. Positive typing for HLA BT101-positive patients and recurrent attacks of 
optic neuritis were associated with an increased incidence of MS. 
5. The presence of MBP in the CSF of a patient with otherwise isolated optic 
neuritis and no history of previous neurologic symptoms or signs is highly 
predictive of the development of MS. 
6. Multiple oligoclonal bands in the CSF of a patient with isolated optic 
neuritis also is a highly predictive of future development of MS.  
7. A positive family history of MS, a history of previous neurologic 
symptoms, and a history of a previous attack of optic neuritis in the fellow 
eye increased the risk of the development of multiple sclerosis.  
8. The patients in whom optic neuritis is the initial manifestation of multiple 
sclerosis tends to have a more benign course than patients in whom 
multiple sclerosis presents with non visual symptoms and signs. 
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OPTIC NEURITIS IN MULTIPLE SCLEROSIS 
 
Pathology 
In patients with acute multiple sclerosis shows active demyelinating 
plaques similar to those in the brain. In such plaques, the inflammatory response is 
marked by perivascular cuffing of T cells and plasma cells. Initially there is 
swelling of nerve tissue in the area of demyelination following which the myelin 
sheath begins to break down into fat droplets. As the degeneration proceeds the 
nerve fibres are destroyed in both proximal and distal segment. After the 
inflammatory reaction subsides, fat laden macrophages become numerous and 
there is a glial proliferation. Primarily the papillomacular bundle was affected, 
peripheral fibres are also affected. There was an increase of cellularity of the 
nerve especially with respect to glial cells. The surface of optic disc showed 
extensive gliosis and the blood vessels on and near the disc were thickened
24
. The 
retina shows atrophy of the nerve fibres and ganglion cells mostly at the macula.  
 
Pathogenesis of visual loss in optic neuritis: 
Demyelination of nerve fibres that causes complete conduction block, 
slowing of conduction, or failure to transmit rapid train of impulses. 
 
Relation of optic neuritis to multiple sclerosis: 
Optic neuritis occurs in about 50% of the patients with MS and in about 
20% of MS patients optic neuritis is the presenting feature.  
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Age 
Younger the age at presentation with optic neuritis  greater is  the risk for 
the development of  multiple sclerosis. The risk of multiple sclerosis increased 
with increasing age. The relative risk for development of multiple sclerosis 
increased by 1.7 for each decade less than 54 yrs.  
 
Gender 
The relative risk of MS is almost three times greater in women. 
 
Features of optic neuritis
24
 
Multiple sclerosis developed in only 13% of 45 patients with anterior optic 
neuritis compared with 60% of 30 patients with retrobulbar neuritis. The presence 
of severe disc swelling reduces the likelihood that MS will develop particularly 
when the patient has also normal MR imaging. Adult patients with bilateral 
simultaneous optic neuritis have the same risk of developing multiple sclerosis 
and patients with unilateral optic neuritis. The ultimate visual acuity after optic 
neuritis has no bearing on the subsequent development of multiple sclerosis. 
 
The fellow eye have a greater risk of developing MS. Recurrent optic 
neuritis will increase the risk for MS.  
 
Cerebrospinal fluid changes    
Evidence of immunologic dysfunction in the CSF is common in patients 
with MS. Oligoclonal bands are noted in CSF. 
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MR imaging was found to a much stronger indicator of risk than HLA 
association but the combination of MR and HLA haplotype DRB1-1501 increased 
the predictive ability significantly.  
 
CHRONIC DEMYELINATING OPTIC NEURITIS 
Patients with chronic demyelinating optic neuritis complain of static 
disturbance of vision, slowly progressive loss in one or bothe eyes or occasionally 
stepwise loss of vision unassociated with periods of recovery. Such patients are 
found to have chronic optic neuritis by clinical testing like colour vision, visual 
field, opththalmoscopy, electrophysiological testing like VEP, psychophysical 
testing like contrast sensitivity or a combination of all these methods.  Most 
patients with chronic unilateral or bilateral demyelinating optic neuritis develop 
visual symptoms after other signs and symptoms of MS have developed. It is the 
reason why the percentage of patients with MS and evidence of chronic 
progressive optic neuritis increases with longer follow-up
25
.   
 
ASYMPTOMATIC OR SUBCLINICAL DEMYELINATING 
OPTIC NEURITIS 
Patients with MS have clinical or laboratory evidence of optic nerve 
dysfunction even though they have no visual complaints. Visually Evoked 
Potential seems to be particularly sensitive indicator of optic nerve and other 
visual sensory pathway disturbances in such patients.  
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NEUROMYELITIS OPTICA 
Acute optic neuropathy preceded or followed within days to weeks by a 
transverse or ascending myelitis. It occurs commonly in children and young 
adults. Both sexes are equally affected. It has been reported in patients with 
systemic lupus erythematosis, pulmonary tuberculosis, and after chickenpox.  
 
Both neuromyelitis optica and myelinoclastic diffuse sclerosis are variants 
of MS. The brain, optic nerve and spinal cord are affected by scattered lesions of 
demyelination that principally affect the white matter. Sometimes it may affect the 
grey matter also. Neuromyelitis optica cases shows evidence of a severe 
necrotizing myelopathy with thickening of blood vessels and absence of 
lymphocytic infiltration or demyelination in the spinal cord. The spinal cord is 
extensively affected in neuromyelitica optica. There is widespread destruction of 
myelin sheath and axis cylinders are also destroyed. There may be small areas of 
perivascular lymphocytosis in both brain and spinal cord. Formation of glial 
tissues occurs in mild or moderatedly severe cases. Small areas of demyelination 
are present in the basal ganglia in the region of red nucleus and in perivascular 
locations throughout the mesencephalon. Cerebellum is almost never affected in 
neuromyelitis optica whereas it is frequently affected in MS. Formation of cavities 
is common in NMO whereas it is rare in MS. Gliosis is characteristic of MS but is 
almost absent in NMO. Arcuate fibres located in the cerebral sub cortex are 
relatively unaffected in NMO.  
 
The primary feature of NMO is visual loss either caused by damage to the 
anterior visual sensory pathway and paraplegia caused by damage to spinal cord. 
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NMO occurs as single episode without recurrences unlike MS. Patients with NMO 
develop mild febrile illness several days or weeks before the onset of visual or 
neurological manifestations. Visual loss is always bilateral. One eye is usually 
affected first then the other eye is affected within hours, days or rarely weeks after 
onset. Loss of vision is typically rapid and severe. The pupils become dilated and 
not reacting to light. The rapid bilateral loss of vision in NMO is in contrast to 
loss of vision in optic neuritis which tends to be unilateral and as severe and loss 
of vision in the Leber’s hereditary optic neuropathy which tends to be more 
slowly progressive. Foci of demyelination that affect optic nerve are irregular and 
occur in different locations. Central scotoma is the most common field defect
24
. 
Most of the patients have mild swelling of the optic disc with dilatation of retinal 
veins with extensive peripapillary exudates.  
 
Visual acuity usually begins to improve within one week after visual 
symptom. CSF analysis shows increase in concentration of protein, oligoclonal 
bands are rarely detected. Neuroimaging consistently shows features of 
demyelination of spinal cord. There is no specific treatment for NMO. Supportive 
care is crucial to ensure survival in patients with severe myelitis. The use of 
intravenous corticosteroids lessens the severity of the attack and increase the 
speed of recovery of both visual and motor function. Intravenous gamma globulin 
can also be given. The mortality rate in patients with neuromyelitis optica is as 
high as 50%. The visual as well as motor recovery is incomplete. Some patients 
are left with severe bilateral visual loss.  
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OPTIC NEURITIS IN MYELINOCLASTIC DIFFUSE SCLEROSIS 
(ENCEPHALITIS PERIAXIALIS DIFFUSA, SCHILDER’S DISEASE) 
Myelinoclastic diffuse sclerosis, are non familial, do not follow an 
obviously viral exanthema, and are not characterized pathologically by inclusion 
bodies or viral particles in the CNS. It is characterised by large, sharply outlined, 
asymmetric focus of demyelination with severe, selective myelinoclasia that often 
affects an entire lobe or cerebral hemisphere. There is typically an extension 
across the corpus callosum and damage to the opposite hemisphere. Examination 
of optic nerve, brain-stem, cerebellum and spinal cord often discloses typical 
discrete lesions consistent with MS. The histopathological examination reveals 
reminiscent of MS. So it is closely related to MS.  
 
Myelinoclastic diffuse sclerosis occurs most often in children and young 
adults. It is characterised by a progressive course that may be steady and 
unremitting or punctuated by a series of episodes of rapid worsening. Cortical 
blindness, irritability and central deafness can occur. The frequency of optic 
neuritis is less compared to MS. The fundus appearance resembles retinitis 
punctata albescens. Accumulation of abnormal material present in the inner aspect 
of internal limiting membrane. The protein content of CSF is slightly increased. 
IgG is often increased. Neuroimaging shows large multifocal extensive areas of 
demyelination. The diagnosis of myelinoclastic diffuse sclerosis is suspected 
when a child or young adult develops evidence of a subacute chronic progressive 
neurological disease with neuroimaging and laboratory evidence of focal 
hemispheric demyelinating disease
24
.  
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ENCEPHALITIS PERIAXIALIS CONCENTRICA (CONCENTRIC 
SCLEROSIS OF BALO)  
Clinically it resembles myelinoclastic diffuse sclerosis but is different 
pathologically. It is characterised clinically by a very rapid course during which 
patients develop a variety of neurological signs separated in both space and time 
including visual loss and diplopia. The visual loss that occurs here is usually 
caused by damage to post geniculate visual pathways and is characterised by 
homonymous field defects and cortical blindness. The pathologic changes include 
alternating bands of demyelination and preserved myelin in series of concentric 
rings in the cerebral white matter. Neuroimaging studies are initially normal. 
However eventually it shows multiple lesions consistent with demyelination. 
Treatment with systemic corticosteroids result in both immediate and long term 
improvement in neurological symptoms and signs.  
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OPTIC NEURITIS DUE TO CAUSES OTHER THAN 
PRIMARY DEMYELINATION 
 
VIRAL AND BACTERIAL DISEASES:  
This typically follows the onset of a viral or, less often a bacterial infection 
by one to three weeks. It is more common in children than in adults. It is due to 
immunological response producing demyelination of optic nerve. Optic neuritis 
may be unilateral but frequently bilateral. Parainfectious optic neuritis whether 
viral or bacterial may occur in patients with no evidence of neurologic 
manifestations or can be associated with meningitis, meningoencephalitis, or 
encephalomyelitis. Visual recovery following parainfectious optic neuritis is 
usually excellent without treatment. It is not known if corticosteroids hasten 
recovery in parainfectious optic neuritis. But this treatment is reasonable to 
consider particularly in cases with severe bilateral visual loss
25
. Optic neuritis has 
been reported in association with viruses like adenovirus, Coxsackie virus, CMV, 
hepatitis A & B, EBV, HIV type 1, measles and bacteria like anthrax, beta 
haemolytic streptococcus, brucellosis, cat scratch disease, pertussis and typhoid. 
Syphilis cause both neuroretinitis and optic perineuroretinitis. Optic neuritis in 
HIV patients can be retrobulbar or anterior optic neuritis.  
 
OPTIC NEURITIS AFTER VACCINATION: 
 Most of the cases are bilateral. Optic neuritis has been reported after 
Hepatitis B, Rabies, BCG, Tetanus toxoid and Variola vaccine. 
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OPTIC NEURITIS IN SARCOIDOSIS: 
            Granulomatous inflammation of optic nerve may occur in sarcoidosis 
producing a typical anterior or retrobulbar neuritis. 
 
OPTIC NEURITIS IN SYSTEMIC LUPUS ERYTHEMATOSIS: 
Usually SLE is associated with typical anterior optic neuritis. The term 
autoimmune optic neuritis has been suggested for cases of optic neuritis in which 
there is serological evidence of vasculitis, progressive visual loss that tends to be 
responsive to treatment with systemic corticosteroids.  
 
BILATERAL OPTIC NEURITIS 
In adults bilateral optic neuritis is particularly associated with multiple 
sclerosis and is uncommon. Incidence of bilateral optic neuritis in MS is 10-75%. 
This is common in children  and  mostly due to viral infection. 
 
OPTIC NEURITIS IN CHILDREN 
The characteristic feature is anterior optic neuritis. It is usually bilateral 
and simultaneous. It occurs within one to two weeks after a known or presumed 
viral infection. It is less often associated with development of MS. It is mostly 
steroid sensitive and steroid dependent. Despite the initial poor visual acuity in 
optic neuritis in children, the visual prognosis appears to be quite good. Children 
younger than 14 years of age tended to have anterior optic neuritis whereas 
retrobulbar neuritis is more common in children more than 14 years of age. In 
younger patients, the cause of inflammation seems to be viral infection or chronic 
focal infection
24
. Older children often had underlying neurological disease. Optic 
neuritis is associated with severe disc swelling.  
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OBJECTIVE 
 
This is a prospective and retrospective study done to evaluate the factors 
influencing the visual outcome of optic neuritis.  
 
The objective of the study is to evaluate the effect of risk factors and the 
treatment given on the visual outcome of optic neuritis. 
 
METHODOLOGY (MATERIALS AND METHODS) 
 
Subject Selection: 
All patients diagnosed as optic neuritis in RIO-GOH during May 2010 to   
May 2012 were included in the study. 
 
Inclusion criteria: 
All patients diagnosed as optic neuritis were studied. 
 
Exclusion criteria: 
The following patients were excluded from the study 
1) Patients with Anterior Ischemic optic neuropathy 
2) Patients with traumatic optic neuropathy 
 
 
 
 42 
 
Methods: 
In patients attending RIO GOH diagnosed as optic neuritis 
1) Various risk factors associated with causation of optic neuritis were 
assessed. 
2) Time of onset of symptoms & time when the patient presented to hospital 
was noted. 
3) In all these patients, visual function was evaluated by Snellen’s chart for 
visual acuity, colour vision by Ishihara pseudoisochromatic chart, 
assessment of contrast sensitivity Peli Robson chart and fields were tested 
manually by Bjerrum’s screen. Pupillary assessment was done and fundus 
examination was done using direct ophthalmoscopy. 
4) Systemic Evaluation was done for diseases causing optic neuritis.   
5) The patients were started on corticosteroids as in ONTT, 3 days of I.V 
Methyl prednisolone at a dose of 500mg twice daily followed by 
Tab.Prednisolone 1mg/kg/day for 11 days and then a short taper. 
6) If there were any contraindications for starting steroids, physician opinion 
was obtained. 
7)  They were also supplemented with inj.vit B1B6B12 on alternate days. 
8) Related investigations were done. 
9) Vision, pupil, field, colour vision, contrast sensitivity and fundus were 
assessed after treatment. 
10) Follow up visits were given two weeks, one month and three months after 
the initial discharge.  
11) Analysis of aetiology and visual outcome of recurrent optic neuritis was 
done. 
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Screening procedures  
Procedures 
1) Vision, Pupillary assessment, Fundus, Fields, Colour vision, contrast 
sensitivity. 
2) B Scan, VEP, MRI Brain and orbit as needed 
 
Follow up procedures/visits 
 Follow up visits were given two weeks, one month and three months after 
the initial discharge. During each follow up assessment of vision, pupil, fundus, 
fields, contrast sensitivity and colour vision were done. 
 
ASSESSMENT OF PARAMETERS  
Visual acuity, Pupillary assessment (Afferent pupillary defect), Fields 
(Central field defect) Colour vision (dyschromatopsia disproportionate to visual 
loss), contrast sensitivity, Fundus changes (swollen optic nerve head) and MRI (in 
case of multiple sclerosis). 
 
Statistical analysis of visual outcome of optic neuritis was done in relation 
to the risk factors and treatment given. 
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OBSERVATION AND RESULTS 
 
Totally 116 patients with acute optic neuritis were included in the study. 
This included first episode, recurrent episode, unilateral and bilateral cases. There 
were 94 unilateral patients and 22 bilateral patients were studied. Totally 138 eyes 
with optic neuritis were studied.  
 
AGE DISTRIBUTION 
Table 1 Age distrubution of the study patients 
 No. Of patients % of total 
< 12 years 12 10.34% 
12 -18 years 7 6.05% 
19-30 years 22 18.96% 
31-50 yrs 57 49.14% 
>50 yrs 18 15.51% 
 
Of the total 116 patients 12 were under the age group of <12 yrs (10.34%). 
Seven (6.05%) patients belong to the age group of 13 – 18 years of age. 22 
(18.96%) patients were in the age group of 19-30 yrs, 57 (49.14%)  in 31-50 yrs 
and 18 (15.51%)  patients were >50 yrs of age. (Figure 1) Majority of the patients 
come under the age group of 31 – 50 yrs of age.  Less number of patients were in 
the age group of 13- 18 yrs of age group. (Table 1) 
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Figure 1 Age distribution 
 
 
SEX DISTRIBUTION: 
Table 2 Sex distribution 
 No. Of patients % of total 
Male 42 36.21% 
Female 74 63.79% 
Total 116 100 
 
Totally there were 116 patients of which 74 females (63.79%) were 
affected. Males were about 42 in number (36.21%). (Table 2) So females were 
commonly affected. (Figure 2) 
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Figure 2 Sex distribution 
 
AGE SEX DISTRIBUTION 
Table 3 Age Sex distribution 
 Male patients 
% among the 
age group 
Female 
patients 
% among the 
age group 
< 12 years 4 33.33 8 66.67 
12 -18 years 3 42.86 4 57.14 
19-30 years 7 31.81 15 68.18 
31-50 yrs 22 38.60 35 61.40 
>50 yrs 6 33.33 12 66.67 
 42  74  
 
Comparing the age and sex distribution female preponderance was seen in 
all age groups. (Figure3)  The difference was less in 12 – 18 yrs age group.  
(Table 3) 
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Figure 3 Sex Age distribution 
 
 
COMPLAINTS 
Table 4 Complaints of the patients 
 No. Of patients % of total 
Defective vision 116 100 
Ocular pain 70 60.34 
Defective colour vision 32 27.58 
Defective field of vision 28 24.14 
 
All the patients presented with defective vision(100%). (Figure 4) 70 
patients had ocular pain (60.34%). Defective colour vision was present in 32 
patients (27.58%). 28 patients had defective field of vision. (24.14%). (Table 4) 
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Figure 4 Complaints of the patients 
 
 
RECURRENT ATTACK 
Table 5 Recurrent cases of optic neuritis 
 No. of cases % of total 
First episode 104 89.66 
Second episode 12 10.34 
 
Of the total 116 acute episode of optic neuritis, 12 patients had history of 
previous attack (10.34%). (Figure 5) Of these 12, 8 gave history of treatment 
taken (66.67% of recurrence) and 4 patients had not taken treatment (33.34%) 
(Table 5) Of the 12 recurrent cases , 7 patient had attack in the same eye itself 
(58.33%) and 5 had attack in the other eye (41.67%)  (Figure 6). 
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Figure 5 Recurrent cases of optic neuritis 
 
 
 
Figure 6 Pattern of Recurrence 
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RELEVANT PAST HISTORY: 
Table 6 Relevant past history 
 No. Of patients % of total 
Drug intake 1 0.86% 
Diabetes mellitus 15 12.93% 
Trauma 0 0 
Fever 7 6.03% 
vaccination 0 0 
Similar episodes in 
family 
0 0 
 
There was history of antituberculosis treatment taken in one patient before 
8 months (Table 6). There was history of fever in 7 patients (6.03%). There was 
no history of trauma, vaccination, family history. (Figure 7,8) 
 
Figure 7 Relevant past history 
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Figure 8 Past history 
 
 
COMPLETE HEMOGRAM 
Table 7 Complete hemogram 
 No. of patients % of total 
Normal 107 92.24% 
Abnormal 9 7.75% 
 
Complete hemogram showed abnormal results indicative of infection in 9 
patients (7.75%) and it was normal in 107 patients (92.24%) (Table 7) (Figure 9) 
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Figure 9 Complete hemogram 
 
 
CHEST X RAY 
Chest X-ray was normal in all the patients. 
 
MRI BRAIN  
 
Figure 10 MRI of the study population 
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MRI brain was advised in atypical cases such as bilateral optic neuritis, 
recurrence optic neuritis and who do not respond to treatment. But due to cost 
factor, MRI was done in seven patients. Of them, 4 were found to be normal 
(3.45%), in 2 cases there was suggestion of demyelination (1.72%) and in one 
patient there was finding of optic neuritis (0.86%). (Figure 10) 
 
VEP 
VEP was done in three patients to confirm the diagnosis of optic neuritis. 
All the three cases showed features of demyelinating optic neuritis. 
 
ABNORMAL INVESTIGATIONS: 
 
Figure 11 Abnormal investigations 
 
Abnormal hemogram was noted in 7 patients (7.75%), MRI was abnormal  
in 3 patients (2.58%)  and VEP was abnormal in 3 patients (2.58%). (Figure 11) 
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VISUAL ACUITY AT THE TIME OF PRESENTATION 
Table 8 Visual acuity at the time of presentation 
 No. Of cases % of total eyes 
PL+ 6 4.35 
CFCF – 6/60 56 40.57 
6/36 – 6/18 67 48.56 
6/12 – 6/9 9 6.52 
 138 100 
 
At the time of presentation 6 had only perception of light (4.34%), 56 had 
vision between CFCF and 6/60 (40.47%), 67 had vision of 6/36-6/18 (48.55) and 
9 had vision of 6/12 – 6/9 (6.52%).  (Table 8) Majority of the patients were with 
vision of 6/36-6/18.  Only very few patients had vision of PL and 6/12-6/6. 
(Figure 12) 
 
Figure 12 Visual acuity at the time of presentation 
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LATERALITY 
Table 9 Laterality of the eyes 
 No. of patients % of total 
Unilateral 94 81.03 
Bilateral 22 18.97 
 
94 patients presented with unilateral optic neuritis (81.03%) and 22 
presented with bilateral optic neuritis (18.97%). (Table 9) (Figure 13) 
 
Figure 13 Laterality of the eyes 
 
 
PUPILLARY REACTION AT THE TIME OF PRESENTATION 
Table 10 Pupillary reaction at the time of presentation 
 No. Of cases % of total 
Normal 0 0 
RAPD 94 68.12 
Ill sustained 44 31.88 
 138 100 
94 
22 
Unilateral 
Bilateral 
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Figure 14 Pupillary reaction at the time of presentation 
 
Among the 116 patients, RAPD was noted in 94 persons (81.03%) and ill 
sustained reaction was noted in bilateral cases (18.93%) (Figure 14). Pupillary 
abnormality was noted in all the study patients (Table 10).  
 
COLOUR VISION AT PRESENTATION 
Table 11 Colour vision at presentation 
 No. Of cases % of total 
Normal 12 8.69 
Defective 103 74.74 
Not possible 23 16.67 
 138 100 
 
Colour vision abnormality (red desaturation) was noted in 103 patients 
(74.74%). Colour vision examination was not possible in 23 patients (16.67%) due 
to poor vision. It was normal in 12 patients (8.69%) (Figure 15). Most of the cases 
showed abnormal colour vision at the time of presentation (Table 11). 
94 
44 
RAPD 
Ill sustained(bilateral) 
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Figure 15 Colour vision at presentation 
 
 
CONTRAST SENSITIVITY 
Table 12 Contrast sensitivity 
 No. Of cases % of total 
Normal 0 0 
Defective  115 83.33 
Not possible 23 16.67 
 138 100 
 
Contrast sensitivity could not be tested in 23 patients due to poor vision 
(16.67%). (Figure 16)  In all possible patients contrast sensitivity was abnormal 
(83.33%) (Table 12) 
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Figure 16 Contrast sensitivity 
 
 
FIELDS AT THE TIME OF PRESENTATION 
Figure 17 Fields at time of presentation 
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At the time of presentation, field charting was not possible in 44 patients 
(31.88).  Central scotoma was present in 41 patients (29.71%) . Centrocaecal 
scotoma and non specific changes were noted in 8 (5.80%) and 45 (32.61%) 
respectively (Table 13). Central scotoma and non specific changes were more 
common (Figure 17).  
 
Table 13 Fields at time of presentation 
 No. Of cases % of total 
Normal 0 0 
Central scotoma 41 29.71 
Centrocecal scotoma 8 5.80 
Non specific 45 32.61 
Not possible 44 31.88 
 
FUNDUS AT THE TIME OF PRESENTATION 
Table 14 Fundus at time of presentation 
 No. Of cases % of total 
Normal 39 28.26 
Abnormal 99 71.74 
Temporal pallor 0 0 
 138 100 
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Figure 18 Fundus at time of presentation 
 
Fundus showed features of anterior optic neuritis including optic disc 
edema, haemorrhages and venous dilatation in 99 patients (71.74%). Fundus was 
normal in 39 patients (28.26%). Anterior optic neuritis was more common than 
retrobulbar neuritis (Table 14) (Figure 18). 
 
Figure 19 Optic neuritis fundus 
 
28.26% 
71.74% 
Normal 
Optic neuritis 
0% 
20% 
40% 
60% 
80% 
100% 
Disc Edema 
Haemorrhages 
Venous dilatation 
100% 
15% 
35% 
 61 
 
In abnormal fundus, disc edema was present in all cases. Haemorrhages 
was noted in 15% and venous dilatation in 35% (Figure 19). 
ONTT: 
All patients were given ONTT. 
 
POST TREATMENT VISUAL ACUITY – ONE WEEK 
Table 15 Post treatment visual acuiy – one week 
Post treatment Visual Acuity one week 
VISUAL ACUITY No. Of patients Percentage of patients (%) 
PL+ 0 0 
CFCF – 6/60 0 0 
6/36 – 6/18 32 23.18 
6/12 – 6/9 42 30.44 
6/6 64 46.38 
 
After one week of treatment 32 patients had visual acuity of 6/36 – 6/18 
(32%), 42 were with visual acuity of 6/12 – 6/6 (30.44%) and 64 (46.38%) had 
visual acuity of 6/6. (Table 15) 
 
POST TREATMENT COLOUR VISION – ONE WEEK 
Table 16 Post treatment Colour vision – one week 
 No. Of cases % of total 
Normal 36 26.09 
Defective 102 73.91 
Not possible 0 0 
 138 100 
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Post treatment, colour vision became normal in 26% patients and remained 
defective in 73% of patients. (Table 16) 
 
POST TREATMENT PUPIL – ONE WEEK 
Table 17 Post treatment pupil – one week 
 No. Of cases % of total 
Normal 84 60.87 
RAPD 0 0 
Ill sustained 54 39.13 
 138 100 
 
After one week of treatment, pupillary reaction was ill sustained in 54 eyes 
(39.13%). It was normal in 84 eyes (60.87%). (Table 1) 
 
POST TREATMENT FUNDUS – ONE WEEK 
Table 18 Post treatment fundus – one week 
 No. Of cases % of total 
Normal 124 89.86 
Abnormal 14 10.14 
Temporal pallor 0 0 
 138 100 
 
One week after treatment fundus was normal in 89% of patients. It 
remained abnormal in 10% of patients (Table 18) (Figure 20). 
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Figure 20 Post treatment fundus – one week 
 
 
POST TREATMENT – ONE MONTH 
One month after presentation 85 patients (61.59%) had visual acuity of 6/6 
(Table 19). Only 12 patients had visual acuity less than 6/18.  After one month of 
treatment, Colour vision remained defective in 63% of individuals (Table 20). 
Pupillary abnormality persisted in 26% of patients (Table 21). Fundus abnormality 
persisted in only 2 patients (1.45%) (Table 22) (Figure 21). 
 
Table 19 Post treatment visual acuity – one month 
Post Operative Visual Acuity – one month 
VISUAL ACUITY No. Of patients Percentage of patients (%) 
6/36 – 6/18 12 12.69 
6/12 – 6/9 41 29.72 
6/6 85 61.59 
 138 100 
 
89.86% 
10.14% 
Normal 
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POST TREATMENT COLOUR VISION – ONE MONTH 
Table 20 Post treatment colour vision – one month 
 No. Of cases % of total 
Normal 50 36.23 
Defective 88 63.77 
Not possible 0 0 
 138 100 
 
POST TREATMENT PUPIL – ONE MONTH 
Table 21 Post treatment pupil – one month 
 No. Of cases % of total 
Normal 101 73.19 
RAPD 0 0 
Ill sustained 37 26.81 
 138 100 
 
POST TREATMENT FUNDUS – ONE MONTH 
Table 22 Post operative fundus – one month 
 No. Of cases % of total 
Normal 136 98.55 
Abnormal 2 1.45 
Temporal pallor 0 0 
 138 100 
 
 
 65 
 
Figure 21 Post treatment visual acuity – one month 
 
POST TREATMENT VISUAL ACUITY – THREE MONTHS 
After three months of treatment, 65% had vision of 6/6 (Table 23). But 
colour vision defect persisted in 60% of the patients (Table 24). Pupillary 
abnormality persisted in 23% of patients (Table 25). Fundus showed temporal 
pallor in 11 patients (7.97%) (Table 26) (Figure 22) 
 
Table 23 Post treatment visual acuity – three months 
Post treatment Visual Acuity – three months 
6/36 – 6/18 8 5.79 
6/12 – 6/9 40 28.98 
6/6 90 65.23 
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POST TREATMENT COLOUR VISION – THREE MONTHS 
Table 24 Postoperative Colour vision – three months 
 No. Of cases % of total 
Normal 55 39.86 
Defective 83 60.14 
Not possible 0 100 
 138 100 
 
POST TREATMENT PUPIL – THREE MONTHS 
Table 25 Postoperative pupil – three months 
 No. Of cases % of total 
Normal 106 76.81 
RAPD 0 0 
Ill sustained 32 23.19 
 138 100 
 
POST TREATMENT FUNDUS – THREE MONTHS 
Table 26 Postoperative Fundus – three months 
 No. Of cases % of total 
Normal 127 92.03 
Abnormal 0 0 
Temporal pallor 11 7.97 
 138 100 
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Figure 22 Post treatment Fundus – three months 
 
 
COMPARISION OF PARAMETERS ONE WEEK, ONE 
MONTH, THREE MONTHS POST TREATMENT WITH PRE-
TREATMENT PARAMETERS 
Visual acuity improvement was significant in one and three months of 
treatment. Colour vision defect persisted in significant percent of patients even 
after three months. Pupillary reaction remained abnormal in 23% of patients. 
Fundus remained abnormal only in 1% after one month. Fundus showed temporal 
pallor in 11 patients after three months ( Figure 23). 
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Table 27 Visual acuity comparison before and after treatment 
  Post treatment 
 Presentation One week One month Three months 
PL+ 4.35 - - - 
CFCF – 6/60 40.57 - - - 
6/36 – 6/18 48.56 23.18 12.69 5.79 
6/12 – 6/9 6.52 30.44 29.72 28.98 
6/6 - 46.38 61.59 65.23 
P value *  0.030** 0.006*** 0.002*** 
*by chi square test 
**significant at p < 0.05 
***significant at p<0.01 
Colour vision comparison before and after treatment 
 
Table 28 Colour vision comparison before and after treatment 
  Post treatment 
 Presentation One week One month Three 
months 
Normal 8.69 26.09 36.23 39.86 
Defective 74.74 73.91 63.77 60.14 
Not possible 16.67 0 0 0 
P value *  0.232 0.112 0.105 
*by chi square test 
Pupillary reaction compared prior and after treatment 
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Table 29 Pupillary reaction comparison before and after treatment 
  Post treatment 
 Presentation One week One month Three months 
Normal 0 60.87 73.19 76.81 
RAPD 68.12 0 0 0 
Ill sustained 31.88 39.13 26.81 23.19 
 
Fundus changes compared prior and after treatment 
Table 30 Fundus  before and after treatment 
  Post treatment 
 Presentation One week One month Three months 
Normal 28.26 89.86 98.55 92.03 
Abnormal 71.74 10.14 1.45 0 
Temporal pallor 0 0 0 7.97 
 
 
Figure 23 Visual parameters before and after ONTT 
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Fundus picture of patient no 106 showing optic disc  oedema 
 
 
AP of patient 106 showing non specific defect 
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VEP of patient No.106 showing reduced N100 amplitude 
 
 
 
FFA of Patient No. 45 showing leakage of optic  
disc in optic neuritis 
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Fundus picture of patient No. 8 showing left sided optic neuritis 
 
AP of patient No. 8 showing central scotoma 
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Fundus picture of Patient No. 47   showing left optic neuritis 
 
 
Fundus of patient No. 63 showing left optic neuritis 
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AP of patient 37 showing centroceacal scotoma 
 
 
MRI of patient No. 33 showing Bilateral optic neuritis
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DISCUSSION 
 
All cases of optic neuritis reporting to our hospital during a period of two 
years were taken for study to assess the efficacy of treatment on various visual 
parameters including visual acuity, colour vision, pupil, fundus and fields. 
Analysis was done as regards to association of any specific risk factors with the 
final visual outcome. 
 
In this study, totally 116 patients with 138 eyes affected with optic neuritis 
were studied. Among these, 50% of the patients were in the age group of 30 – 50 
years which was also noted in the ONTT study.  Only 6% was reported in the age 
group of 12 – 18 yrs. 
 
64% of cases were females indicating a female preponderance. This 
female preponderance persisted through all age groups.  
 
Defective vision was reported in 100% patients. Defective colour vision 
was reported in 30%. Field defects were complained in 28% of the patients. 
Although these complaints were co-existent with visual defect, the probable cause 
of this might be poor visual acuity so that colour vision and fields could not be 
complained of by these patients.  
 
History of recurrence i.e. previous attack of sudden loss of vision which 
improved later with or without treatment was present in 10% of individuals.   
Approximate intervals between recurrences was 2 years in this study. History of 
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treatment was present in 65% of recurrent cases. But there was no difference in 
interval between two attack noted between the two groups (with or without 
treatment).  
 
Recurrence was more common in the same eye (58%) compared to 
recurrence in other eye.  
 
Considering the past history, history of fever was present in 6% of 
patients. Fever was more common in children. History of treatment taken for 
tuberculosis was present in one patient. There was no history of trauma or recent 
vaccination.  
 
MRI was advised in atypical cases. It was done in seven patients in whom 
4 were normal. Two patients showed signs of demyelination. One patient showed 
feature of optic neuritis. MRI showing demyelination in the periventricular region 
is a strong predictor of future development of multiple sclerosis.  
 
Most of the cases were unilateral in 80% of patients. Bilateral cases were 
common in children. History of fever was more common in children which were 
suggestive of possibility of viral etiology for optic neuritis.  
 
Visual acuity at the time of presentation was 6/36-6/18 in 48% of patients. 
Only 4% had PL vision. Colour vision was defective in 75% of patients at the time 
of presentation. Contrast sensitivity and fields were defective in all patients who 
had vision enough to be tested.  Central scotoma was present in 42% of patients 
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and non specific defects were noted in 45% of patients. During follow up fields 
were tested by Bjerrum’s screen. Those who had abnormal field were subjected to 
automated perimetry at three months all of whom showed persistent field defect. 
Abnormal pupillary reaction was noted in all the patients. Even after treatment 
pupillary abnormality persisted in 25% of patients. Retro bulbar neuritis was noted 
in 28% of the patients. Fundus abnormalities were resolved by three months in all 
patients. 8% of patients developed temporal pallor at three months of follow up 
indicating some residual damage to optic nerve.  
 
After ONTT, visual acuity abnormalities resolved in 76% of patients by 
one month and 94% in three months. Colour vision and contrast sensitivity 
abnormality persisted even after three months.  
 
ONTT hastened improvement of visual acuity in all the patients with optic 
neuritis. 
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CONCLUSION 
 Females were predominantly affected than males in the ratio of 3:1. 
 Most common affected patients were in the age group of 30-50 yrs. 
 Recurrent cases included 10% of the patients.  Recurrence was more common 
in the same eye. 
 No specific association with any etiological factor was noted. 
 Almost all patients had defective vision. Around 25% had complaints of 
defective colour vision, defective field of vision and 60% had ocular pain. 
 Bilateral cases were around 18%. They were more common in children. 
 Fever was more common in children and more commonly associated with 
bilateral optic neuritis. 
 Visual acuity at the time of presentation was 6/60 – 6/36. In all the patients 
pupillary reaction was abnormal. Colour vision was abnormal in 75% of 
patients. Contrast sensitivity was abnormal in all patients. 
 Field defect was always noted in all patients most common was central 
scotoma.  
 Retrobulbar neuritis was noted in 28% of patients. Other patients had optic 
neuritis. Most commonly disc oedema was noted. Rarely haemorrhage was 
noted.  
 After ONTT almost all patients showed improvement in vision. This 
improvement of vision is statistically significant.  
 Colour vision recovery was noted in 46% after three months of follow up. 
 Fields showed persistent field defect after three months in the patients. 
 Institution of ONTT has definite role in speeding up of recovery.   
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PROFORMA FOR FACTORS INFLUENCING OUTCOME 
OF OPTIC NEURITIS 
 
Name  
Age/Sex  
O.P./I.P. No.  
Date  
Address  
 
 
Contact No.  
Unit  
Diagnosis  
Complaints  
 
History 
Sl.No. Complaints  
 1.  Loss/Blurring of Vision     -    Onset 
                                                  Duration  
                                                  Progression 
                                                  Whether increased with 
                                                     - exercise or hot bath 
                                                     - bright light 
 
 2. Pain  -   Associated with movement of eyeball 
              Tender sore eye 
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 3. Distorted Vision  
 4. Black area with in visual field  
 5.   Decrease in Peripheral Vision  
 6. Defective colour vision esp  red  
 7.  Flashes of light  
 8. Loss of contrast sensitivity  
 9. History related to orbital inflammation  -  eye swelling 
                                                                    proptosis 
 
 
Relevant History 
Sl. No.                                       History  
 1. Fever, Head ache, Nausea, Vomiting  
 2. H/o. alcohol intake ( methylated spirit )  
 3  H/o. Tobacco smoking / chewing / snuffing  
 4. H/o. Tuberculosis, Syphilis  
 5. H/o. Viral infections ( Herpes, measles, mumps, HBV, HIV)   
 6. H/o. Sinusitis  
 7. H/o. Diabetes mellitus  
 8. H/0. Seizures  
 9. H/o. Thyroid disease (Grave s)  
 10. H/o. Drug intake eg. Ethambutol, INH, Streptomycin, 
                                  Chloramphenicol,   Amiodarone                       
 
 11. H/o. Radiation to head  
 12. H/o. Exposure to toxins eg. Lead, arsenic  
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 13. H/o. Bee sting  
 14. H/o. Vaccination  eg. Influenza, Hepatitis B, Measles  
 15. H/o. Similar episode (loss of vision) before  
 16. H/o. Similar episode in other family members  
 
EXAMINATION:  
GENERAL EXAMINATION: 
Physical Examination:  Built 
                                       Nourishment 
                                      Anemia 
                                       Temperature 
                                       Features related to autoimmune disease 
                                       Musculoskeletal system 
                                       Skin 
CNS Examination : 
          Higher functions – 
          Motor system – 
          Sensory system – 
          Cerebellar system – 
           Spinal cord – 
Abdominal examination : 
Cardiovascular system : 
Respiratory system : 
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OCULAR EXAMINATION:        SLIT LAMP EXAMINATION 
 
                             RE                 LE 
Visual Acuity   
Lids   
Conjunctiva   
Cornea   
AC   
Pupil     
Normal / RAPD 
Direct 
Indirect 
 
Normal / RAPD 
Direct 
Indirect 
Iris   
Lens   
Intra ocular tension   
Extra ocular movements   
Pain / tenderness on mvt of 
eyeball 
  
 
 
Colour Vision                                RE                                 LE 
 
 
Intra Ocular Tension                    RE                                 LE 
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Fundus Examination: 
                     Direct Ophthalmoscopy      Media 
                                                                 Optic disc 
                                                                 CD ratio 
                     Indirect Opthalmoscopy 
 
Retinoscopy and AR subjective 
Field of Vision 
             RE                  LE 
Manual   
AP   
 
Inference : 
 
PROVISIONAL DIAGNOSIS 
INVESTIGATIONS: 
Ocular Investigations : 
1.  FFA 
2. B Scan 
3. Visual  Evoked Potential 
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General investigations : 
1. Complete hemogram 
          TC 
          DC 
          ESR 
           Hb 
2. VDRL 
3. Mantoux test 
4. Chest X Ray 
5. MRI  Brain with Gadolinum contrast 
 
Management 
Investigation summary 
Positive Findings Negative Findings 
 
 
 
 
Treatment 
Intravenous treatment 
Date Steroids Neuro vitamins Methyl Prednisolone Dose 
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 Treatment Summary: 
 
Visual Acuity during treatment period 
 
Date 
 
Day of admission 
Visual Acuity 
RE LE 
    
    
    
    
    
    
 
 
FOLLOW UP : 
 
     Date 
Visual Acuity Field of Vision Colour Vision  
            Fundus 
 
  Pupil  RE  LE  RE   LE  RE   LE 
         
         
         
         
         
         
         
         
 
  
 
 
 
Master Chart
  
 
 
 
 
 
Pre Treatment Chart 
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X
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V
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P
 
                RE LE RE LE RE LE RE LE RE LE RE LE           
1 Visalam 29 F a,b - - N 6/6 6/36 N RAPD N Ab N ↓ N ↓ N CS Given N N     
2  Muthiah 33 M a,b,c - a+ N 6/6 5/60 N RAPD N Ab N ↓ N ↓ N CS Given N N 
 
  
3 Ashik Nisha 56 F a,b - - N 6/6 6/36 N RAPD N Ab N ↓ N ↓ N CS Given N N     
4 Annamalai 34 M a,b,c - - N 5/60 6/6 RAPD N Ab N ↓ N ↓ N CS N Given N N     
5 Gowthami 7 F a,b + - N 5/60 4/60 Ill Ill Ab Ab ↓ NP ↓ NP NP NP Given Ab N     
6 Koilmani 28 M a - - N 6/6 PL N RAPD N Ab N NP N NP N NP Given N N     
7 Kalaiarasi 33 F a,b - a- N 5/60 6/6 RAPD N N N ↓ N ↓ N CC N Given N N     
8 Sujatha 54 F a - - N 6/6 6/24 N RAPD N Ab N ↓ N ↓ N CS Given N N     
9 Therasa 32 F a,b,c - - N 3/60 6/6 RAPD N N N NP N NP N NP N Given N N     
10 Imayavalli 6 F a - - N 6/36 6/6 RAPD N Ab N ↓ N ↓ N NP N Given Ab N     
11 Kameswari 52 F a,c - a+ N 6/18 6/6 RAPD N Ab N ↓ N ↓ N NS N Given N N     
12 Shanthi 24 F a,b,d - - N 5/60 6/6 RAPD N N N ↓ N ↓ N CS N Given N N     
13 Sadhurya 4 F a + - N 6/36 6/36 Ill Ill Ab Ab ↓ ↓ ↓ ↓ NP NP Given Ab N     
14 Vignesh 36 M a,b,c - - N 6/9 6/6 RAPD N N N ↓ N ↓ N CC N Given N N     
15 Sirisha 51 F a,c - e N 6/6 6/36 N RAPD N Ab N ↓ N ↓ N NS Given N N     
16 Anjali 15 F a,b,d - - N 6/6 2/60 N RAPD N N N NP N NP N NP Given N N     
17 Jayanthi 27 F a - - N 6/24 6/18 Ill Ill Ab Ab ↓ ↓ ↓ ↓ NS NS Given N N Ab   
Patients No : 1 -17 
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                RE LE RE LE RE LE RE LE RE LE RE LE           
18 Radha 51 F a,b - - N 6/12 6/6 RAPD N Ab N ↓ N ↓ N CS N Given N N     
19 Madhusudhan 5 M a,c + - N 6/18 6/6 RAPD N Ab N ↓ N ↓ N NP N Given Ab N     
20 Arockiamary 53 F a,b,d - - N HM 6/6 RAPD N Ab N NP N NP N NP N Given N N     
21 Kanniappan 22 M a - - N 6/36 6/24 Ill Ill Ab Ab ↓ ↓ ↓ ↓ NS NS Given N N     
22 Munikannan 17 M a,b,c - - N 6/6 1/60 N RAPD N Ab N NP N NP N NP Given N N     
23 Elumalai 42 M a,c - a+ N PL 6/6 RAPD N Ab N NP N NP N NP N Given N N     
24 Lakshmi.S 22 F a,b - - N 6/6 3/60 N RAPD N Ab N NP N NP N NP Given N N     
25 Kalaivani 24 F a + - N 6/36 6/18 Ill Ill Ab Ab ↓ ↓ ↓ ↓ NP NP Given Ab N     
26 Srijith 54 M a,b,c - e N 6/6 5/60 N RAPD N Ab N ↓ N ↓ N CC Given N N     
27 Hari 43 M a - b N CFCF 6/6 RAPD N Ab N NP N NP N NP N Given N N     
28 Kesarvaman 25 M a,b,c + - N 6/24 6/36 Ill Ill Ab Ab ↓ ↓ ↓ ↓ NS NS Given Ab N N   
29 Suseela 57 F a,b - e N 6/36 6/6 RAPD N Ab N N N ↓ N CS N Given N N     
30 Kumar 56 M a,c - - N 6/9 6/6 RAPD N Ab N ↓ N ↓ N CS N Given N Ab     
31 Maryammal 54 F a,b - e N 6/6 3/60 N RAPD N Ab N NP N NP N NP Given N N     
32 Sivagami 35 F a,b - - N 6/6 6/24 N RAPD N Ab N ↓ N ↓ N CC Given N N     
33 Anitha 7 F a,b,c - a+ N 5/60 3/60 Ill Ill Ab Ab ↓ NP ↓ NP NP NP Given N N Ab   
34 Hemalatha 52 F a,b - - N 6/6 3/60 N RAPD N Ab N NP N NP N NP Given N N     
35 Kamala 14 F a,c - - N 6/36 6/18 Ill Ill Ab Ab ↓ ↓ ↓ ↓ NS CS Given N N N   
Patients No : 18 - 35 
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                RE LE RE LE RE LE RE LE RE LE RE LE           
36 Valliammal 37 F a,b,c - a- N 5/60 6/6 RAPD N Ab N ↓ N ↓ N CS N Given N N     
37 Padma 38 F a - - N 5/60 6/6 RAPD N Ab N ↓ N ↓ N CC N Given N N     
38 Mahesh 54 M a,b,c - e N 6/24 6/6 RAPD N Ab N ↓ N ↓ N NS N Given N N     
39 Manoharan 6 M a,b + - N 5/60 6/6 RAPD N Ab N ↓ N ↓ N NP N Given Ab N     
40 Govindaraj 34 M a,b,c - - N 5/60 6/6 RAPD N Ab N ↓ N ↓ N CS N Given N N   ON 
41 Kothandaraman 35 M a,b - - N 6/36 6/18 Ill Ill Ab Ab ↓ ↓ ↓ ↓ NS CS Given N N     
42 Perumal 52 M a,b,c - - N 6/36 6/6 RAPD N Ab N N N ↓ N CC N Given N N     
43 Nagammal 25 F a,b,d - - N HM 6/6 RAPD N N N NP N NP N NP N Given N N     
44 Nalini 11 F a,b,c - - N 6/36 6/24 Ill Ill Ab Ab ↓ ↓ ↓ ↓ NP NP Given N N     
45 Annadurai.K 48 M a,b,d - e N 6/36 6/6 RAPD N N N ↓ N ↓ N NS N Given N N     
46 Ashok Kumar 35 M a - a+ N 6/12 6/6 RAPD N Ab N N N ↓ N NS N Given N N     
47 Arunkumar 20 M a,b,c - - N 6/6 6/60 N RAPD N Ab N ↓ N ↓ N CS Given N N     
48 Saravanan 37 M a,b,d - - N 6/6 3/60 N RAPD N Ab N NP N NP N NP Given N N     
49 AnilBabu 37 M a,b - - N 6/6 5/60 N RAPD N Ab N ↓ N ↓ N CS Given N N     
50 Selvi 30 F a,b,c,d - - N 5/60 6/6 RAPD N N N ↓ N ↓ N CS N Given N N     
51 ChadraBose 37 M a,c - - N HM 6/6 RAPD N Ab N NP N ↓ NP NP N Given N N     
52 Nedunchezian 17 M a,b,d - - N 6/36 6/24 Ill Ill N N ↓ ↓ ↓ ↓ NS NS Given N N     
53 Raja 52 M a - - N 6/12 6/6 RAPD N Ab N ↓ N ↓ N NS N Given N N   ON 
Patients No : 36 - 53 
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                RE LE RE LE RE LE RE LE RE LE RE LE           
54 Geetha 56 F a,c,d - - N 6/6 1/60 N RAPD N Ab N NP N NP N NP Given N N     
55 Valliamma 15 F a,b - - N 6/6 6/18 N RAPD N N N N N ↓ N CC Given N N     
56 Lakshmi.K 40 F a,b,d - a+ N 6/6 6/60 N RAPD N N N N N ↓ N NS Given N N     
57 Mariammal 56 F a,b,d - - N 5/60 6/6 RAPD N Ab N ↓ N ↓ N CS N Given N N     
58 Duraisamy 39 M a - e N HM 6/6 RAPD N N N NP N ↓ NP NP N Given N N     
59 Iyappan 11 M a,b - - N 6/36 6/24 Ill Ill Ab Ab ↓ ↓ ↓ ↓ NP NP Given N N     
60 Arasalingam 41 M a - - N 5/60 6/6 RAPD N N N ↓ N ↓ N CS N Given N N     
61 Gunasekaran 39 M a,b,d - - N 6/36 6/6 RAPD N N N ↓ N ↓ N NS N Given N N     
62 Rajendran 56 M a,b,d - - N 6/18 6/6 RAPD N Ab N ↓ N ↓ N NS N Given N N     
63 Abitha 6 F a,b - - N 6/6 6/36 N RAPD N Ab N ↓ N ↓ N NP Given N N     
64 Suseela raman 57 F a,b,d - - N 6/6 5/60 N RAPD N Ab N ↓ N ↓ N CC Given N N     
65 Thanam 29 F a,d - - N 5/60 HM Ill Ill N N ↓ NP ↓ NP NS NP Given N N     
66 Ramar 44 M a - e N 1/60 6/6 RAPD N Ab N NP N NP N NP N Given N N   ON 
67 Subalakshmi 42 F a - e N 5/60 6/6 RAPD N Ab N ↓ N ↓ N CS N Given N N     
68 Rani 48 F a - e N 6/6 6/9 N RAPD N Ab N ↓ N ↓ N CS Given N N     
69 Annammal 45 F a,c,d - a- N 6/6 6/18 N RAPD N N N ↓ N ↓ N NS Given N N Ab   
70 Subramaniam 29 M a - - N 6/36 6/24 Ill Ill Ab Ab ↓ ↓ ↓ ↓ NS NS Given N N     
71 Santhanam 46 M a,b,c,d - - N 6/6 1/60 N RAPD N Ab N NP N NP N NP Given N N     
Patients No : 54 - 71 
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                RE LE RE LE RE LE RE LE RE LE RE LE           
72 Mohan 14 M a,b - - N 6/24 6/36 Ill Ill Ab Ab ↓ ↓ ↓ ↓ NS NS Given N N N   
73 Kumaran 35 M a,b - - N 6/36 6/6 RAPD N Ab N ↓ N ↓ N CC N Given N N     
74 Marial 26 F a,b - a+ N PL 6/6 RAPD N N N NP N NP N NP N Given N N N   
75 Jeevanandam 36 M a - - N 5/60 6/6 RAPD N Ab N ↓ N ↓ N NS N Given N N     
76 Tamilarasan 48 M a,b,d - - N 6/36 6/6 RAPD N Ab N N N ↓ N CS N Given N N     
77 Subbammal 43 F a - - N 5/60 6/6 RAPD N N N ↓ N ↓ N CS N Given N N     
78 Sabari 51 F a,b - - N 5/60 6/6 RAPD N Ab N ↓ N ↓ N CS N Given N N     
79 Thangalaxmi 26 F a,d - - N 6/36 6/18 Ill Ill Ab Ab ↓ ↓ ↓ ↓ NS NS Given N N N   
80 Rajathi 38 F a,b,c - - N 6/6 6/24 N RAPD N N N ↓ N ↓ N CS Given N N     
81 Amala 18 F a,b - - N 5/60 5/60 Ill Ill Ab Ab ↓ ↓ ↓ ↓ NS NS Given N N     
82 Parvathy 36 F a,b,c - - N 6/36 6/6 RAPD N N N ↓ N ↓ N CS N Given N N     
83 Chitrarani 46 F a,b - - N 6/36 6/6 RAPD N Ab N N N ↓ N NS N Given N N     
84 Lakshmi 42 F a,b,c,d - - N 5/60 6/6 RAPD N N N ↓ N ↓ N CS N Given N N     
85 Uma 4 F a - - N 6/36 6/6 RAPD N Ab N N N ↓ N NP N Given N N     
86 Kailasam 49 F a,b,d - - N 6/6 6/12 N RAPD N Ab N ↓ N ↓ N CS Given N N     
87 Meena 27 F a - - N 6/36 6/18 Ill Ill Ab Ab ↓ ↓ ↓ ↓ NS NS Given N N     
88 Sornam 38 F a,b,c,d - - N 6/6 5/60 N RAPD N N N ↓ N ↓ N CS Given N N     
89 Sorimuthu 32 M a - - N PL 6/6 RAPD N Ab N NP N NP N NP N Given N N     
Patients No : 72 -89 
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                RE LE RE LE RE LE RE LE RE LE RE LE           
90 Palaniammal 39 F a,b - - N 6/6 5/60 N RAPD N N N ↓ N ↓ N CS Given N N     
91 Vijaya 42 F a - - N 6/6 6/9 N RAPD N Ab N ↓ N ↓ N CS Given N N     
92 Sivam 49 M a,b - - N 6/6 6/36 N RAPD N Ab N ↓ N ↓ N NS Given N N     
93 Bargavy 43 F a - e N 6/6 6/24 N RAPD N Ab N ↓ N ↓ N CS Given N N     
94 Kavitha 43 F a,b - - N 6/6 5/60 N RAPD N Ab N ↓ N ↓ N CS Given N N     
95 Kannammal 35 F a - - N PL 6/6 RAPD N N N NP N NP N NP N Given N N     
96 Sekar 12 M a,b + - N 6/36 6/36 Ill Ill Ab Ab ↓ ↓ ↓ ↓ NP NP Given Ab N     
97 Baby 36 F a,b,d - - N 6/6 6/36 N RAPD N N N ↓ N ↓ N CS Given N N     
98 Jothi 37 F a,c - - N 5/60 6/6 RAPD N N N ↓ N ↓ N CS N Given N N     
99 Rajalakshmi 24 F a,d - - N 6/18 6/36 Ill Ill N N ↓ ↓ ↓ ↓ NS NS Given N N     
100 Subarani 33 F a - - N 6/36 6/6 RAPD N N N ↓ N ↓ N CS N Given N N     
101 Kalai 42 F a,c - e N 5/60 6/6 RAPD N N N ↓ N ↓ N CS N Given N N     
102 Shoba 49 F a - - N 6/6 5/60 N RAPD N N N ↓ N ↓ N CS Given N N     
103 Subashree 21 F a,b,d - - N 6/36 6/24 Ill Ill Ab Ab ↓ ↓ ↓ ↓ NS NS Given N N     
104 Vani 45 F a,b - e N 6/6 6/36 N RAPD N Ab N ↓ N ↓ N CS Given N N     
105 Annadurai.D 31 M a,b,c - a- N 6/6 5/60 N RAPD N N N ↓ N ↓ N NS Given N N     
106 Nithi 42 F a,d - - N 6/60 6/6 RAPD N N N N N ↓ N NS N Given N N     
107 Suba 41 F a,b - - N 6/6 PL N RAPD N Ab N NP N NP N NP Given N N     
Patients No : 90 - 107 
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                RE LE RE LE RE LE RE LE RE LE RE LE           
108 Thangam 12 F a - - N 6/36 6/18 Ill Ill Ab Ab ↓ ↓ ↓ ↓ NP NP Given Ab N     
109 Latha 47 F a,b,d - e N 6/6 6/36 N RAPD N Ab N N N ↓ N NS Given N N     
110 Shruti 22 F a,b - - N 6/6 6/60 N RAPD N N N ↓ N ↓ N NS Given N N     
111 Raji 37 F a - e N 5/60 6/6 RAPD N Ab N ↓ N ↓ N CS N Given N N     
112 Jayamaran 22 M a,b,d - - N 6/24 6/6 RAPD N N N ↓ N ↓ N NS N Given N N     
113 Revathy 34 F a,d - - N 6/6 6/9 N RAPD N Ab N ↓ N ↓ N CS Given N N     
114 Reka 28 F a - - N 6/36 6/6 RAPD N Ab N ↓ N ↓ N CS N Given N N     
115 Rajammal 35 F a,b - a+ N 1/60 6/6 RAPD N N N NP N NP N NP N Given N N     
116 Meenakumari 35 F a - - N 5/60 6/6 RAPD N N N ↓ N ↓ N NS N Given N N     
 
 
 
 
 
Patients No : 108 - 116 
  
 
 
 
 
 
Post Treatment Chart 
 
  
       One week One month Three months 
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        RE LE RE LE RE LE RE LE RE LE RE LE RE LE RE LE RE LE RE LE RE LE RE LE RE LE 
1 Visalam 29 F 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓     
2 Muthiah 33   6/6 6/36 N ill N Ab N ↓ 6/6 6/24 N ill N N N N 6/6 6/18 N ill N N N N    
3 Ashik Nisha 56 F 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N     
4 Annamalai 34 M 6/6 6/6 N N Ab N ↓ N 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N     
5 Gowthami 7 F 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N     
6 Koilmani 28 M 6/6 6/9 N N N N N ↓ 6/6 6/9 N N N N N ↓ 6/6 6/9 N N N N N ↓     
7 Kalaiarasi 33 F 6/36 6/6 ill N N N N N 6/36 6/6 ill N N N N N 6/9 6/6 ill N N N N N     
8 Sujatha 54 F 6/6 6/18 N ill N N N ↓ 6/6 6/18 N ill N N N N 6/6 6/6 N N N N N N     
9 Therasa 32 F 6/18 6/6 ill N N N N N 6/6 6/6 ill N N N N N 6/6 6/6 N N N N N N     
10 Imayavalli 6 F 6/24 6/6 ill N N N ↓ N 6/6 6/6 ill N N N N N 6/24 6/6 ill N N N N N     
11 Kameswari 52 F 6/12 6/6 N ill N N N N 6/9 6/6 N N N N N N 6/6 6/6 N N N N N N     
12 Shanthi 24 F 6/18 6/6 ill ill N N ↓ N 6/9 6/6 ill N N N ↓ N 6/9 6/6 ill N N N N N     
13 Sadhurya 4 F 6/18 6/12 ill ill N N ↓ ↓ 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N     
14 Vignesh 36 M 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N     
15 Sirisha 51 F 6/6 6/18 N N N Ab N ↓ 6/6 6/18 N N N Ab N ↓ 6/6 6/18 N N N N N ↓     
16 Anjali 15 F 6/6 6/36 N ill N N N N 6/6 6/6 N ill N N N N 6/6 6/6 N ill N N N N     
17 Jayanthi 27 F 6/12 6/12 ill ill N N N ↓ 6/9 6/12 ill ill N N N N 6/9 6/12 ill ill N Tp N N N NS 
Patients No : 1 -17 
       One week One month Three months 
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18 Radha 51 F 6/9 6/6 N N N N ↓ N 6/9 6/6 N N N N ↓ N 6/9 6/6 N N N N ↓ N     
19 Madhusudhan 5 M 6/12 6/6 N ill N N ↓ N 6/12 6/6 N N N N ↓ N 6/12 6/6 N N N N ↓ N     
20 Arockiamary 53 F 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N     
21 Kanniappan 22 M 6/18 6/12 ill ill N N ↓ ↓ 6/9 6/12 ill ill N N N ↓ 6/9 6/6 ill ill N N N ↓     
22 Munikannan 17 M 6/6 6/9 N N N N N ↓ 6/6 6/9 N N N N N ↓ 6/6 6/9 N N N N N ↓     
23 Elumalai 42 M 6/36 6/6 ill N N N ↓ N 6/9 6/6 N N N N ↓ N 6/9 6/6 N N N N ↓ N     
24 Lakshmi.S 22 F 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N     
25 Kalaivani 24 F 6/18 6/12 N ill N N N ↓ 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N     
26 Srijith 54 M 6/6 6/36 N ill N N N N 6/6 6/36 N ill N N N N 6/6 6/36 N N N N N N     
27 Hari 43 M 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N     
28 Kesarvaman 25 M 6/12 6/6 N ill N N ↓ ↓ 6/12 6/6 N ill N N ↓ ↓ 6/12 6/6 N ill N Tp ↓ ↓ NS NS 
29 Suseela 57 F 6/18 6/6 ill N N N N N 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N     
30 Kumar 56 M 6/9 6/6 ill N Ab N ↓ N 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N     
31 Maryammal 54 F 6/6 6/9 N N N N N ↓ 6/6 6/9 N N N N N ↓ 6/6 6/9 N N N N N ↓     
32 Sivagami 35 F 6/6 6/12 N ill N N N ↓ 6/6 6/9 N ill N N N ↓ 6/6 6/9 N ill N N N N     
33 Anitha 7 F 6/12 6/12 N N N N ↓ N 6/9 6/9 N Ill N N ↓ N 6/9 6/9 N Ill N N ↓ N     
34 Hemalatha 52 F 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓     
35 Kamala 14 F 6/12 6/12 N ill N N ↓ ↓ 6/6 6/12 N ill N N N N 6/6 6/12 N ill N Tp N N N CS 
36 Valliammal 37 F 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N     
37 Padma 38 F 6/9 6/6 N N Ab N ↓ N 6/9 6/6 N N Ab N N N 6/9 6/6 N N N N N N     
38 Mahesh 54 M 6/18 6/6 ill N N N N N 6/9 6/6 ill N N N N N 6/9 6/6 ill N N N N N     
Patients No : 18 -38 
       One week One month Three months 
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39 Manoharan 6 M 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N     
40 Govindaraj 34 M 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N     
41 Kothandaraman 35 M 6/6 6/6 N N N N ↓ ↓ 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓     
42 Perumal 52 M 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N 6/6 6/6 N N Tp N N N N CC 
43 Nagammal 25 F 6/36 6/6 ill N N N N N 6/6 6/6 ill N N N N N 6/6 6/6 ill N N N N N     
44 Nalini 11 F 6/6 6/6 N N N N ↓ ↓ 6/6 6/6 N N N N ↓ ↓ 6/6 6/6 N N N N ↓ ↓     
45 Annadurai.K 48 M 6/9 6/6 N N N N ↓ N 6/9 6/6 N N N N ↓ N 6/9 6/6 N N N N ↓ N     
46 Ashok Kumar 35 M 6/9 6/6 ill N N N N N 6/9 6/6 N N N N N N 6/9 6/6 N N N N N N     
47 Arunkumar 20 M 6/6 6/24 N ill N N N ↓ 6/6 6/9 N ill N N N ↓ 6/6 6/9 N ill N N N ↓     
48 Saravanan 37 M 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N     
49 AnilBabu 37 M 6/6 6/24 N ill N N N ↓ 6/6 6/24 N ill N N N ↓ 6/6 6/6 N N N N N ↓     
50 Selvi 30 F 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N 6/6 6/6 N N Tp N N N N CS 
51 ChadraBose 37 M 6/36 6/6 ill N N N ↓ N 6/36 6/6 ill N N N ↓ N 6/6 6/6 ill N N N ↓ N     
52 Nedunchezian 17 M 6/9 6/6 N N N N ↓ ↓ 6/9 6/6 N N N N ↓ ↓ 6/9 6/6 N N N N ↓ ↓     
53 Raja 52 M 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N     
54 Geetha 56 F 6/6 6/36 N ill N N N N 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N     
55 Valliamma 15 F 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N     
56 Lakshmi.K 40 F 6/6 6/18 N ill N N N N 6/6 6/9 N ill N N N N 6/6 6/9 N ill N N N N     
57 Mariammal 56 F 6/24 6/6 ill N N N ↓ N 6/6 6/6 ill N N N ↓ N 6/6 6/6 ill N N N ↓ N     
58 Duraisamy 39 M 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N     
59 Iyappan 11 M 6/6 6/6 N N Ab Ab ↓ ↓ 6/6 6/6 N N N N ↓ ↓ 6/6 6/6 N N N N ↓ ↓     
Patients No : 39 -59 
       One week One month Three months 
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60 Arasalingam 41 M 6/9 6/6 N N N N ↓ N 6/9 6/6 N N N N ↓ N 6/9 6/6 N N N N ↓ N     
61 Gunasekaran 39 M 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N     
62 Rajendran 56 M 6/6 6/6 ill N N N N N 6/6 6/6 ill N N N N N 6/6 6/6 ill N Tp N N N N NS 
63 Abitha 6 F 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓     
64 Suseela raman 57 F 6/6 6/9 N N N N N ↓ 6/6 6/9 N N N N N ↓ 6/6 6/9 N N N N N ↓     
65 Thanam 29 F 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N     
66 Ramar 44 M 6/9 6/6 N N N N ↓ N 6/9 6/6 N N N N ↓ N 6/9 6/6 N N N N ↓ N     
67 Subalakshmi 42 F 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N     
68 Rani 48 F 6/6 6/9 N N N Ab N ↓ 6/6 6/9 N N N N N ↓ 6/6 6/9 N N N N N ↓     
69 Annammal 45 F 6/6 6/12 N ill N N N ↓ 6/6 6/9 N N N N N ↓ 6/6 6/9 N N N N N ↓     
70 Subramaniam 29 M 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N 6/6 6/6 N N Tp N ↓ N NS NS 
71 Santhanam 46 M 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓     
72 Mohan 14 M 6/6 6/9 N N N N ↓ ↓ 6/6 6/9 N N N N ↓ ↓ 6/6 6/9 N N N N ↓ ↓     
73 Kumaran 35 M 6/12 6/6 ill N Ab N ↓ N 6/12 6/6 N N N N ↓ N 6/12 6/6 N N N N ↓ N     
74 Marial 26 F 6/24 6/6 ill N N N N N 6/18 6/6 ill N N N N N 6/18 6/6 ill N N N N N     
75 Jeevanandam 36 M 6/18 6/6 ill N N N ↓ N 6/6 6/6 ill N N N ↓ N 6/6 6/6 ill N N N ↓ N     
76 Tamilarasan 48 M 6/18 6/6 ill N N N N N 6/6 6/6 ill N N N N N 6/6 6/6 ill N N N N N     
77 Subbammal 43 F 6/18 6/6 ill N N N ↓ N 6/6 6/6 ill N N N ↓ N 6/6 6/6 ill N N N ↓ N     
78 Sabari 51 F 6/6 6/6 N N Ab N N N 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N     
79 Thangalaxmi 26 F 6/12 6/12 N N N N ↓ ↓ 6/12 6/12 N Ill N N ↓ ↓ 6/12 6/12 N Ill N N ↓ ↓     
80 Rajathi 38 F 6/6 6/12 N ill N N N ↓ 6/6 6/6 N ill N N N ↓ 6/6 6/6 N ill N N N ↓     
Patients No : 60-80 
       One week One month Three months 
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81 Amala 18 F 6/6 6/6 N N N N ↓ ↓ 6/6 6/6 N N N N ↓ ↓ 6/6 6/6 N N N N ↓ ↓     
82 Parvathy 36 F 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N     
83 Chitrarani 46 F 6/9 6/6 N N N N N N 6/9 6/6 N N N N N N 6/9 6/6 N N N N N N     
84 Lakshmi 42 F 6/18 6/6 ill N N N ↓ N 6/18 6/6 N N N N ↓ N 6/18 6/6 N N Tp N ↓ N CS NS 
85 Uma 4 F 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N     
86 Kailasam 49 F 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓     
87 Meena 27 F 6/6 6/6 ill N N N ↓ ↓ 6/6 6/6 ill N N N ↓ ↓ 6/6 6/6 ill N N N ↓ ↓     
88 Sornam 38 F 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓     
89 Sorimuthu 32 M 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N     
90 Palaniammal 39 F 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓     
91 Vijaya 42 F 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓     
92 Sivam 49 M 6/6 6/12 N ill N N N ↓ 6/6 6/6 N ill N N N ↓ 6/6 6/6 N N N N N ↓     
93 Bargavy 43 F 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓     
94 Kavitha 43 F 6/6 6/9 N N N Ab N ↓ 6/6 6/9 N N N N N ↓ 6/6 6/9 N N N N N ↓     
95 Kannammal 35 F 6/24 6/6 N ill N N N N 6/9 6/6 N N N N N N 6/9 6/6 N N N N N N     
96 Sekar 12 M 6/6 6/6 N N N N ↓ ↓ 6/6 6/6 N N N N ↓ ↓ 6/6 6/6 N N N N N ↓     
97 Baby 36 F 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N N     
98 Jothi 37 F 6/12 6/6 ill N N N ↓ N 6/6 6/6 ill N N N ↓ N 6/6 6/6 ill N N N ↓ N     
99 Rajalakshmi 24 F 6/6 6/6 N N N N ↓ ↓ 6/6 6/6 N N N N ↓ ↓ 6/6 6/6 N N N N ↓ ↓     
100 Subarani 33 F 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N     
101 Kalai 42 F 6/24 6/6 ill N N N ↓ N 6/6 6/6 ill N N N ↓ N 6/6 6/6 ill N N N ↓ N     
Patients No : 81-101 
       One week One month Three months 
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102 Shoba 49 F 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓     
103 Subashree 21 F 6/6 6/6 N N N N ↓ ↓ 6/6 6/6 N N N N ↓ ↓ 6/6 6/6 N N N N ↓ ↓     
104 Vani 45 F 6/6 6/9 N N N Ab N ↓ 6/6 6/9 N N N N N ↓ 6/6 6/9 N N N N N ↓     
105 Annadurai.D 31 M 6/6 6/12 N ill N N N ↓ 6/6 6/6 N ill N N N ↓ 6/6 6/6 N N N Tp N ↓ N NS 
106 Nithi 42 F 6/12 6/6 ill N N N N N 6/9 6/6 ill N N N N N 6/9 6/6 ill N N N N N     
107 Suba 41 F 6/6 6/24 N ill N N N N 6/6 6/24 N N N N N N 6/6 6/6 N N N N N N     
108 Thangam 12 F 6/6 6/6 N N N N ↓ ↓ 6/6 6/6 N N N N ↓ ↓ 6/6 6/6 N N N N ↓ ↓     
109 Latha 47 F 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N 6/6 6/6 N N N N N N     
110 Shruti 22 F 6/6 6/36 N ill N N N ↓ 6/6 6/36 N ill N N N ↓ 6/6 6/36 N ill N Tp N N N NS 
111 Raji 37 F 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N 6/6 6/6 N N N N ↓ N     
112 Jayamaran 22 M 6/12 6/6 ill N N N ↓ N 6/12 6/6 ill N N N ↓ N 6/12 6/6 ill N N N ↓ N     
113 Revathy 34 F 6/6 6/6 N N N Ab N ↓ 6/6 6/6 N N N N N ↓ 6/6 6/6 N N N N N ↓     
114 Reka 28 F 6/12 6/6 ill N N N ↓ N 6/9 6/6 N N N N ↓ N 6/9 6/6 N N N N ↓ N     
115 Rajammal 35 F 6/18 6/6 ill N N N ↓ N 6/18 6/6 ill N N N ↓ N 6/18 6/6 N N Tp N ↓ N N CS 
116 Meenakumari 35 F 6/12 6/6 ill N N N ↓ N 6/9 6/6 N N N N ↓ N 6/9 6/6 N N N N ↓ N     
 
Patients No : 102-116 
KEYNOTE TO MASTER CHART 
 
Pupil 
Ill - Illsustained  
RAPD-Relative Afferent Pupillary Defect 
Colour Vision 
N - normal 
↓- Red desaturation 
Complaint 
a - Defective  vision  
b - Pain in the eye 
c - Defective colour vision 
d-Defective field of vision 
Relevant H/o. 
Recurrence - present a treatment taken + not taken - 
Drug intake - b 
Recent vaccination - c 
Trauma H/o. - d 
Diabetes - e 
H/o. Similar episode in other family members - f 
Fundus 
Normal - N 
Abnormal – AbN 
 
 
 Complete hemogram 
Normal - N 
Abnormal - Ab - indicative of infection 
Chest X Ray 
Normal - N 
Abnormal - Ab - indicative of tuberculosis 
MRI Brain 
Normal - N 
Abnormal - Ab -indicative of Multiple sclerosis 
Not done - ND 
ON- s/o optic neuritis 
NP - NOT POSSIBLE due to poor vision 
Field 
Normal N 
Central scotoma  CS 
Centrocecal scotoma cc 
Non specific – NS 
Not done - ND 
ONTT -    optic neuritis treatment trial 
 
